1-1	0-8	Modeling	_	_
1-2	9-19	subjective	_	_
1-3	20-29	relevance	_	_
1-4	30-32	in	_	_
1-5	33-46	schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-6	47-50	and	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-7	51-54	its	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
1-8	55-63	relation	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-9	64-66	to	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-10	67-75	aberrant	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-11	76-84	salience	_	_
1-12	85-87	In	_	_
1-13	88-101	schizophrenia	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-14	101-102	,	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-15	103-112	increased	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-16	113-121	aberrant	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-17	122-130	salience	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-18	131-133	to	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-19	134-144	irrelevant	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-20	145-151	events	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-21	152-155	and	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-22	156-163	reduced	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-23	164-172	learning	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-24	173-175	of	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-25	176-184	relevant	_	_
1-26	185-196	information	_	_
1-27	197-200	may	_	_
1-28	201-207	relate	_	_
1-29	208-210	to	_	_
1-30	211-213	an	_	_
1-31	214-224	underlying	_	_
1-32	225-232	deficit	_	_
1-33	233-235	in	_	_
1-34	236-245	relevance	_	_
1-35	246-255	detection	_	_
1-36	255-256	.	_	_

2-1	257-259	So	_	_
2-2	260-263	far	_	_
2-3	263-264	,	_	_
2-4	265-275	subjective	_	_
2-5	276-285	estimates	_	_
2-6	286-288	of	_	_
2-7	289-298	relevance	_	_
2-8	299-303	have	_	_
2-9	304-307	not	_	_
2-10	308-312	been	_	_
2-11	313-319	probed	_	_
2-12	320-322	in	_	_
2-13	323-336	schizophrenia	_	_
2-14	337-345	patients	_	_
2-15	345-346	.	_	_

3-1	347-350	The	_	_
3-2	351-361	mechanisms	_	_
3-3	362-372	underlying	_	_
3-4	373-379	belief	_	_
3-5	380-389	formation	_	_
3-6	390-395	about	_	_
3-7	396-405	relevance	_	_
3-8	406-409	and	_	_
3-9	410-415	their	_	_
3-10	416-427	translation	_	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
3-11	428-432	into	_	_
3-12	433-442	decisions	_	_
3-13	443-446	are	_	_
3-14	447-454	unclear	_	_
3-15	454-455	.	_	_

4-1	456-461	Using	_	_
4-2	462-467	novel	_	_
4-3	468-481	computational	_	_
4-4	482-489	methods	_	_
4-5	489-490	,	_	_
4-6	491-493	we	_	_
4-7	494-506	investigated	_	_
4-8	507-516	relevance	_	_
4-9	517-526	detection	_	_
4-10	527-533	during	_	_
4-11	534-542	implicit	_	_
4-12	543-551	learning	_	_
4-13	552-554	in	_	_
4-14	555-557	42	_	_
4-15	558-571	schizophrenia	_	_
4-16	572-580	patients	_	_
4-17	581-584	and	_	_
4-18	585-587	42	_	_
4-19	588-595	healthy	_	_
4-20	596-607	individuals	_	_
4-21	607-608	.	_	_

5-1	609-621	Participants	_	_
5-2	622-631	underwent	_	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
5-3	632-642	functional	_	_
5-4	643-651	magnetic	_	_
5-5	652-661	resonance	_	_
5-6	662-669	imaging	_	_
5-7	670-675	while	_	_
5-8	676-685	detecting	_	_
5-9	686-689	the	_	_
5-10	690-698	outcomes	_	_
5-11	699-701	in	_	_
5-12	702-703	a	_	_
5-13	704-712	learning	_	_
5-14	713-717	task	_	_
5-15	717-718	.	_	_

6-1	719-724	These	_	_
6-2	725-729	were	_	_
6-3	730-738	preceded	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
6-4	739-741	by	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
6-5	742-746	cues	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
6-6	747-756	differing	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
6-7	757-759	in	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
6-8	760-765	color	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#Thing
6-9	766-769	and	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#Thing
6-10	770-775	shape	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#Thing
6-11	775-776	,	_	_
6-12	777-782	which	_	_
6-13	783-787	were	_	_
6-14	788-794	either	_	_
6-15	795-803	relevant	_	_
6-16	804-806	or	_	_
6-17	807-817	irrelevant	_	_
6-18	818-821	for	_	_
6-19	822-829	outcome	_	_
6-20	830-840	prediction	_	_
6-21	840-841	.	_	_

7-1	842-844	We	_	_
7-2	845-853	provided	_	_
7-3	854-855	a	_	_
7-4	856-861	novel	_	_
7-5	862-872	definition	_	_
7-6	873-875	of	_	_
7-7	876-885	relevance	_	_
7-8	886-891	based	_	_
7-9	892-894	on	_	_
7-10	895-903	Bayesian	_	_
7-11	904-913	precision	_	_
7-12	914-917	and	_	_
7-13	918-925	modeled	_	_
7-14	926-934	reaction	_	_
7-15	935-940	times	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
7-16	941-943	as	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
7-17	944-945	a	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
7-18	946-954	function	_	_
7-19	955-957	of	_	_
7-20	958-967	relevance	_	_
7-21	968-976	weighted	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-22	977-985	unsigned	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-23	986-996	prediction	_	_
7-24	997-1003	errors	_	_
7-25	1004-1005	(	_	_
7-26	1005-1008	UPE	_	_
7-27	1008-1009	)	_	_
7-28	1009-1010	.	_	_

8-1	1011-1014	For	_	_
8-2	1015-1023	aberrant	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
8-3	1024-1032	salience	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
8-4	1032-1033	,	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
8-5	1034-1036	we	_	_
8-6	1037-1045	assessed	_	_
8-7	1046-1055	responses	_	_
8-8	1056-1058	to	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-9	1059-1071	subjectively	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-10	1072-1082	irrelevant	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-11	1083-1086	cue	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-12	1087-1101	manifestations	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
8-13	1101-1102	.	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging

9-1	1103-1115	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
9-2	1116-1123	learned	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
9-3	1124-1127	the	_	_
9-4	1128-1141	contingencies	_	_
9-5	1142-1145	and	_	_
9-6	1146-1152	slowed	_	_
9-7	1153-1157	down	_	_
9-8	1158-1163	their	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
9-9	1164-1173	responses	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
9-10	1174-1183	following	_	_
9-11	1184-1194	unexpected	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
9-12	1195-1201	events	_	_
9-13	1201-1202	.	_	_

10-1	1203-1208	Model	_	_
10-2	1209-1218	selection	_	_
10-3	1219-1227	revealed	_	_
10-4	1228-1232	that	_	_
10-5	1233-1244	individuals	_	_
10-6	1245-1253	inferred	_	_
10-7	1254-1257	the	_	_
10-8	1258-1267	relevance	_	_
10-9	1268-1270	of	_	_
10-10	1271-1274	cue	_	_
10-11	1275-1283	features	_	_
10-12	1284-1287	and	_	_
10-13	1288-1292	used	_	_
10-14	1293-1295	it	_	_
10-15	1296-1299	for	_	_
10-16	1300-1310	behavioral	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
10-17	1311-1319	adaption	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
10-18	1320-1322	to	_	_
10-19	1323-1326	the	_	_
10-20	1327-1335	relevant	_	_
10-21	1336-1339	cue	_	_
10-22	1340-1347	feature	_	_
10-23	1347-1348	.	_	_

11-1	1349-1358	Relevance	_	_
11-2	1359-1367	weighted	_	_
11-3	1368-1372	UPEs	_	_
11-4	1373-1383	correlated	_	_
11-5	1384-1388	with	_	_
11-6	1389-1395	dorsal	_	_
11-7	1396-1404	anterior	_	_
11-8	1405-1414	cingulate	_	_
11-9	1415-1421	cortex	_	_
11-10	1422-1432	activation	_	_
11-11	1433-1436	and	_	_
11-12	1437-1448	hippocampus	_	_
11-13	1449-1461	deactivation	_	_
11-14	1461-1462	.	_	_

12-1	1463-1465	In	_	_
12-2	1466-1474	patients	_	_
12-3	1474-1475	,	_	_
12-4	1476-1479	the	_	_
12-5	1480-1488	aberrant	_	_
12-6	1489-1497	salience	_	_
12-7	1498-1502	bias	_	_
12-8	1503-1505	to	_	_
12-9	1506-1518	subjectively	_	_
12-10	1519-1534	task-irrelevant	_	_
12-11	1535-1546	information	_	_
12-12	1547-1550	was	_	_
12-13	1551-1560	increased	_	_
12-14	1561-1564	and	_	_
12-15	1565-1575	correlated	_	_
12-16	1576-1580	with	_	_
12-17	1581-1590	decreased	_	_
12-18	1591-1599	striatal	_	_
12-19	1600-1603	UPE	_	_
12-20	1604-1614	activation	_	_
12-21	1615-1618	and	_	_
12-22	1619-1628	increased	_	_
12-23	1629-1637	negative	_	_
12-24	1638-1646	symptoms	_	_
12-25	1646-1647	.	_	_

13-1	1648-1652	This	_	_
13-2	1653-1658	study	_	_
13-3	1659-1664	shows	_	_
13-4	1665-1669	that	_	_
13-5	1670-1679	relevance	_	_
13-6	1680-1689	estimates	_	_
13-7	1690-1695	based	_	_
13-8	1696-1698	on	_	_
13-9	1699-1707	Bayesian	_	_
13-10	1708-1717	precision	_	_
13-11	1718-1721	can	_	_
13-12	1722-1724	be	_	_
13-13	1725-1733	inferred	_	_
13-14	1734-1738	from	_	_
13-15	1739-1747	observed	_	_
13-16	1748-1756	behavior	_	_
13-17	1756-1757	.	_	_

14-1	1758-1762	This	_	_
14-2	1763-1774	underscores	_	_
14-3	1775-1778	the	_	_
14-4	1779-1789	importance	_	_
14-5	1790-1792	of	_	_
14-6	1793-1802	relevance	_	_
14-7	1803-1812	detection	_	_
14-8	1813-1815	as	_	_
14-9	1816-1818	an	_	_
14-10	1819-1829	underlying	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_
14-11	1830-1839	mechanism	_	_
14-12	1840-1843	for	_	_
14-13	1844-1854	behavioral	_	_
14-14	1855-1865	adaptation	_	_
14-15	1866-1868	in	_	_
14-16	1869-1876	complex	_	_
14-17	1877-1889	environments	_	_
14-18	1890-1893	and	_	_
14-19	1894-1902	enhances	_	_
14-20	1903-1906	the	_	_
14-21	1907-1920	understanding	_	_
14-22	1921-1923	of	_	_
14-23	1924-1932	aberrant	_	_
14-24	1933-1941	salience	_	_
14-25	1942-1944	in	_	_
14-26	1945-1958	schizophrenia	_	_
14-27	1958-1959	.	_	_

15-1	1960-1966	Author	_	_
15-2	1967-1974	summary	_	_
15-3	1975-1988	Schizophrenia	_	_
15-4	1989-1997	patients	_	_
15-5	1998-2005	display	_	_
15-6	2006-2014	deficits	_	_
15-7	2015-2017	in	_	_
15-8	2018-2021	the	_	_
15-9	2022-2033	appropriate	_	_
15-10	2034-2045	attribution	_	_
15-11	2046-2048	of	_	_
15-12	2049-2063	meaningfulness	_	_
15-13	2064-2066	to	_	_
15-14	2067-2074	stimuli	_	_
15-15	2074-2075	;	_	_
15-16	2076-2080	such	_	_
15-17	2081-2083	as	_	_
15-18	2084-2094	aberrantly	_	_
15-19	2095-2104	increased	_	_
15-20	2105-2115	processing	_	_
15-21	2116-2118	of	_	_
15-22	2119-2129	irrelevant	_	_
15-23	2130-2133	and	_	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
15-24	2134-2146	insufficient	_	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
15-25	2147-2157	processing	_	_
15-26	2158-2160	of	_	_
15-27	2161-2169	relevant	_	_
15-28	2170-2181	information	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
15-29	2181-2182	.	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_

16-1	2183-2185	We	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
16-2	2186-2191	aimed	_	_
16-3	2192-2194	to	_	_
16-4	2195-2206	investigate	_	_
16-5	2207-2210	the	_	_
16-6	2211-2221	subjective	_	_
16-7	2222-2228	nature	_	_
16-8	2229-2231	of	_	_
16-9	2232-2241	relevance	_	_
16-10	2242-2251	detection	_	_
16-11	2252-2255	and	_	_
16-12	2256-2259	its	_	_
16-13	2260-2267	deficit	_	_
16-14	2268-2270	in	_	_
16-15	2271-2284	schizophrenia	_	_
16-16	2285-2288	and	_	_
16-17	2289-2298	developed	_	_
16-18	2299-2301	an	_	_
16-19	2302-2310	implicit	_	_
16-20	2311-2319	learning	_	_
16-21	2320-2328	paradigm	_	_
16-22	2329-2333	that	_	_
16-23	2334-2341	allowed	_	_
16-24	2342-2345	for	_	_
16-25	2346-2354	parallel	_	_
16-26	2355-2363	learning	_	_
16-27	2364-2368	from	_	_
16-28	2369-2377	relevant	_	_
16-29	2378-2381	and	_	_
16-30	2382-2392	irrelevant	_	_
16-31	2393-2404	information	_	_
16-32	2404-2405	.	_	_

17-1	2406-2411	Based	_	_
17-2	2412-2414	on	_	_
17-3	2415-2418	the	_	_
17-4	2419-2423	idea	_	_
17-5	2424-2428	that	_	_
17-6	2429-2439	subjective	_	_
17-7	2440-2449	relevance	_	_
17-8	2450-2455	might	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
17-9	2456-2458	be	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
17-10	2459-2467	captured	_	_
17-11	2468-2470	by	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
17-12	2471-2479	Bayesian	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
17-13	2480-2489	precision	_	_
17-14	2490-2492	we	_	_
17-15	2493-2496	set	_	_
17-16	2497-2499	up	_	_
17-17	2500-2509	different	_	_
17-18	2510-2523	computational	_	_
17-19	2524-2530	models	_	_
17-20	2531-2533	of	_	_
17-21	2534-2537	how	_	_
17-22	2538-2548	subjective	_	_
17-23	2549-2558	relevance	_	_
17-24	2559-2565	guides	_	_
17-25	2566-2574	learning	_	_
17-26	2575-2578	and	_	_
17-27	2579-2589	behavioral	_	_
17-28	2590-2600	adaptation	_	_
17-29	2600-2601	.	_	_

18-1	2602-2604	We	_	_
18-2	2605-2610	found	_	_
18-3	2611-2615	that	_	_
18-4	2616-2624	subjects	_	_
18-5	2625-2628	use	_	_
18-6	2629-2637	Bayesian	_	_
18-7	2638-2647	precision	_	_
18-8	2648-2650	to	_	_
18-9	2651-2659	estimate	_	_
18-10	2660-2668	stimulus	_	_
18-11	2669-2678	relevance	_	_
18-12	2679-2681	in	_	_
18-13	2682-2687	order	_	_
18-14	2688-2690	to	_	_
18-15	2691-2700	integrate	_	_
18-16	2701-2717	multidimensional	_	_
18-17	2718-2729	information	_	_
18-18	2730-2733	and	_	_
18-19	2734-2739	adapt	_	_
18-20	2740-2744	more	_	_
18-21	2745-2747	to	_	_
18-22	2748-2751	the	_	_
18-23	2752-2764	subjectively	_	_
18-24	2765-2773	relevant	_	_
18-25	2774-2781	stimuli	_	_
18-26	2781-2782	.	_	_

19-1	2783-2787	This	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
19-2	2788-2797	relevance	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
19-3	2798-2806	weighted	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
19-4	2807-2817	adaptation	_	_
19-5	2818-2828	correlated	_	_
19-6	2829-2833	with	_	_
19-7	2834-2839	brain	_	_
19-8	2840-2850	activation	_	_
19-9	2851-2857	within	_	_
19-10	2858-2861	the	_	_
19-11	2862-2870	salience	_	_
19-12	2871-2878	network	_	_
19-13	2878-2879	.	_	_

20-1	2880-2887	Further	_	_
20-2	2887-2888	,	_	_
20-3	2889-2902	schizophrenia	_	_
20-4	2903-2911	patients	_	_
20-5	2912-2921	displayed	_	_
20-6	2922-2924	an	_	_
20-7	2925-2934	increased	_	_
20-8	2935-2943	aberrant	_	_
20-9	2944-2952	tendency	_	_
20-10	2953-2955	to	_	_
20-11	2956-2966	irrelevant	_	_
20-12	2967-2973	events	_	_
20-13	2974-2979	which	_	_
20-14	2980-2987	related	_	_
20-15	2988-2990	to	_	_
20-16	2991-3000	decreased	_	_
20-17	3001-3009	striatal	_	_
20-18	3010-3016	coding	_	_
20-19	3017-3019	of	_	_
20-20	3020-3023	the	_	_
20-21	3024-3032	relevant	_	_
20-22	3033-3041	learning	_	_
20-23	3042-3048	signal	_	_
20-24	3048-3049	.	_	_

21-1	3050-3052	To	_	_
21-2	3053-3061	conclude	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
21-3	3061-3062	,	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
21-4	3063-3066	our	_	_
21-5	3067-3075	findings	_	_
21-6	3076-3087	demonstrate	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
21-7	3088-3091	how	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
21-8	3092-3102	individual	_	_
21-9	3103-3110	beliefs	_	_
21-10	3111-3116	about	_	_
21-11	3117-3126	relevance	_	_
21-12	3127-3130	can	_	_
21-13	3131-3133	be	_	_
21-14	3134-3142	inferred	_	_
21-15	3143-3147	from	_	_
21-16	3148-3161	computational	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
21-17	3162-3168	models	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
21-18	3168-3169	.	_	_

22-1	3170-3181	Furthermore	_	_
22-2	3181-3182	,	_	_
22-3	3183-3185	we	_	_
22-4	3186-3193	suggest	_	_
22-5	3194-3198	that	_	_
22-6	3199-3207	aberrant	_	_
22-7	3208-3216	salience	_	_
22-8	3217-3225	observed	_	_
22-9	3226-3228	in	_	_
22-10	3229-3237	patients	_	_
22-11	3238-3242	with	_	_
22-12	3243-3256	schizophrenia	_	_
22-13	3257-3265	reflects	_	_
22-14	3266-3268	an	_	_
22-15	3269-3282	idiosyncratic	_	_
22-16	3283-3287	bias	_	_
22-17	3288-3290	in	_	_
22-18	3291-3297	states	_	_
22-19	3298-3300	of	_	_
22-20	3301-3305	high	_	_
22-21	3306-3316	subjective	_	_
22-22	3317-3328	uncertainty	_	_
22-23	3328-3329	.	_	_



























































81-1	13468-13477	Materials	_	_
81-2	13478-13481	and	_	_
81-3	13482-13489	methods	_	_
81-4	13490-13496	Ethics	_	_
81-5	13497-13506	statement	_	_
81-6	13507-13510	All	_	_
81-7	13511-13523	participants	_	_
81-8	13524-13528	gave	_	_
81-9	13529-13536	written	_	_
81-10	13537-13545	informed	_	_
81-11	13546-13553	consent	_	_
81-12	13554-13557	and	_	_
81-13	13558-13566	received	_	_
81-14	13567-13575	monetary	_	_
81-15	13576-13588	compensation	_	_
81-16	13589-13591	as	_	_
81-17	13592-13596	well	_	_
81-18	13597-13599	as	_	_
81-19	13600-13603	the	_	_
81-20	13604-13609	total	_	_
81-21	13610-13614	wins	_	_
81-22	13615-13617	of	_	_
81-23	13618-13621	the	_	_
81-24	13622-13626	task	_	_
81-25	13627-13634	battery	_	_
81-26	13634-13635	.	_	_

82-1	13636-13639	The	_	_
82-2	13640-13645	study	_	_
82-3	13646-13649	was	_	_
82-4	13650-13659	performed	_	_
82-5	13660-13662	in	_	_
82-6	13663-13673	accordance	_	_
82-7	13674-13678	with	_	_
82-8	13679-13682	the	_	_
82-9	13683-13694	Declaration	_	_
82-10	13695-13697	of	_	_
82-11	13698-13706	Helsinki	_	_
82-12	13707-13710	and	_	_
82-13	13711-13714	was	_	_
82-14	13715-13723	approved	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
82-15	13724-13726	by	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
82-16	13727-13730	the	_	_
82-17	13731-13736	local	_	_
82-18	13737-13743	ethics	_	_
82-19	13744-13753	committee	_	_
82-20	13754-13756	of	_	_
82-21	13757-13764	Charité	_	_
82-22	13765-13784	Universitätsmedizin	_	_
82-23	13784-13785	.	_	_

83-1	13786-13798	Participants	_	_
83-2	13799-13801	In	_	_
83-3	13802-13807	total	_	_
83-4	13807-13808	,	_	_
83-5	13809-13811	42	_	_
83-6	13812-13825	schizophrenia	_	_
83-7	13826-13834	patients	_	_
83-8	13835-13838	and	_	_
83-9	13839-13840	a	_	_
83-10	13841-13848	matched	_	_
83-11	13849-13856	healthy	_	_
83-12	13857-13864	control	_	_
83-13	13865-13870	group	_	_
83-14	13871-13873	of	_	_
83-15	13874-13876	42	_	_
83-16	13877-13888	individuals	_	_
83-17	13889-13901	participated	_	_
83-18	13902-13904	in	_	_
83-19	13905-13909	this	_	_
83-20	13910-13915	study	_	_
83-21	13915-13916	.	_	_

84-1	13917-13924	Healthy	_	_
84-2	13925-13936	individuals	_	_
84-3	13937-13945	reported	_	_
84-4	13946-13948	no	_	_
84-5	13949-13953	past	_	_
84-6	13954-13956	or	_	_
84-7	13957-13964	present	_	_
84-8	13965-13976	psychiatric	_	_
84-9	13977-13985	disorder	_	_
84-10	13986-13995	according	_	_
84-11	13996-13998	to	_	_
84-12	13999-14002	the	_	_
84-13	14003-14009	SKID-I	_	_
84-14	14009-14010	.	_	_

85-1	14011-14019	Patients	_	_
85-2	14020-14024	were	_	_
85-3	14025-14034	diagnosed	_	_
85-4	14035-14039	with	_	_
85-5	14040-14053	schizophrenia	_	_
85-6	14054-14063	according	_	_
85-7	14064-14066	to	_	_
85-8	14067-14070	the	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
85-9	14071-14077	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
85-10	14078-14081	and	_	_
85-11	14082-14085	ICD	_	_
85-12	14085-14086	-	_	_
85-13	14086-14088	10	_	_
85-14	14088-14089	.	_	_

86-1	14090-14105	Psychopathology	_	_
86-2	14106-14109	was	_	_
86-3	14110-14118	assessed	_	_
86-4	14119-14124	using	_	_
86-5	14125-14128	the	_	_
86-6	14129-14137	Positive	_	_
86-7	14138-14141	and	_	_
86-8	14142-14150	Negative	_	_
86-9	14151-14159	Syndrome	_	_
86-10	14160-14165	Scale	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
86-11	14166-14167	(	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
86-12	14167-14172	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
86-13	14172-14173	)	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
86-14	14174-14176	as	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
86-15	14177-14181	well	_	_
86-16	14182-14184	as	_	_
86-17	14185-14188	the	_	_
86-18	14189-14197	subscale	_	_
86-19	14198-14201	for	_	_
86-20	14202-14211	delusions	_	_
86-21	14212-14215	and	_	_
86-22	14216-14225	anhedonia	_	_
86-23	14226-14228	of	_	_
86-24	14229-14232	the	_	_
86-25	14233-14238	Scale	_	_
86-26	14239-14242	for	_	_
86-27	14243-14246	the	_	_
86-28	14247-14257	Assessment	_	_
86-29	14258-14260	of	_	_
86-30	14261-14269	Positive	_	_
86-31	14270-14271	(	_	_
86-32	14271-14275	SAPS	_	_
86-33	14275-14276	)	_	_
86-34	14277-14280	and	_	_
86-35	14281-14289	Negative	_	_
86-36	14290-14298	Symptoms	_	_
86-37	14299-14300	(	_	_
86-38	14300-14304	SANS	_	_
86-39	14304-14305	)	_	_
86-40	14305-14306	,	_	_
86-41	14307-14319	respectively	_	_
86-42	14320-14321	(	_	_
86-43	14321-14324	for	_	_
86-44	14325-14336	information	_	_
86-45	14337-14339	on	_	_
86-46	14340-14352	demographics	_	_
86-47	14353-14356	and	_	_
86-48	14357-14372	psychopathology	_	_
86-49	14372-14373	,	_	_
86-50	14374-14377	see	_	_
86-51	14378-14383	Table	_	_
86-52	14384-14385	1	_	_
86-53	14385-14386	)	_	_
86-54	14386-14387	.	_	_

87-1	14388-14391	All	_	_
87-2	14392-14400	patients	_	_
87-3	14401-14405	were	_	_
87-4	14406-14408	on	_	_
87-5	14409-14422	antipsychotic	_	_
87-6	14423-14433	medication	_	_
87-7	14434-14435	(	_	_
87-8	14435-14438	for	_	_
87-9	14439-14443	more	_	_
87-10	14444-14451	details	_	_
87-11	14451-14452	,	_	_
87-12	14453-14456	see	_	_
87-13	14457-14462	Table	_	_
87-14	14463-14464	A	_	_
87-15	14465-14467	in	_	_
87-16	14468-14471	the	_	_
87-17	14472-14482	Supplement	_	_
87-18	14482-14483	)	_	_
87-19	14483-14484	.	_	_

88-1	14485-14489	They	_	_
88-2	14490-14494	were	_	_
88-3	14495-14504	recruited	_	_
88-4	14505-14509	from	_	_
88-5	14510-14513	the	_	_
88-6	14514-14523	inpatient	_	_
88-7	14524-14527	and	_	_
88-8	14528-14538	outpatient	_	_
88-9	14539-14544	units	_	_
88-10	14545-14547	of	_	_
88-11	14548-14551	the	_	_
88-12	14552-14562	Department	_	_
88-13	14563-14565	of	_	_
88-14	14566-14576	Psychiatry	_	_
88-15	14577-14580	and	_	_
88-16	14581-14594	Psychotherapy	_	_
88-17	14594-14595	,	_	_
88-18	14596-14623	Charité-Universitätsmedizin	_	_
88-19	14624-14630	Berlin	_	_
88-20	14631-14634	and	_	_
88-21	14635-14638	the	_	_
88-22	14639-14650	Psychiatric	_	_
88-23	14651-14661	Department	_	_
88-24	14662-14664	of	_	_
88-25	14665-14668	the	_	_
88-26	14669-14686	Schlossparkklinik	_	_
88-27	14687-14693	Berlin	_	_
88-28	14693-14694	.	_	_

89-1	14695-14703	Aberrant	_	_
89-2	14704-14712	salience	_	_
89-3	14713-14716	raw	_	_
89-4	14717-14721	data	_	_
89-5	14722-14728	scores	_	_
89-6	14729-14731	of	_	_
89-7	14732-14733	a	_	_
89-8	14734-14743	partially	_	_
89-9	14744-14755	overlapping	_	_
89-10	14756-14762	sample	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
89-11	14763-14764	(	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
89-12	14764-14766	37	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
89-13	14767-14774	healthy	_	_
89-14	14775-14783	controls	_	_
89-15	14784-14787	and	_	_
89-16	14788-14790	34	_	_
89-17	14791-14804	schizophrenia	_	_
89-18	14805-14813	patients	_	_
89-19	14813-14814	)	_	_
89-20	14815-14819	were	_	_
89-21	14820-14828	reported	_	_
89-22	14829-14831	in	_	_
89-23	14832-14833	a	_	_
89-24	14834-14842	previous	_	_
89-25	14843-14854	publication	_	_
89-26	14854-14855	.	_	_

90-1	14856-14867	Demographic	_	_
90-2	14868-14871	and	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	_
90-3	14872-14880	clinical	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
90-4	14881-14896	characteristics	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	_
90-5	14896-14897	.	_	_

91-1	14899-14912	SCHIZOPHRENIA	_	_
91-2	14913-14921	PATIENTS	_	_
91-3	14922-14923	(	_	_
91-4	14923-14924	N	_	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
91-5	14925-14926	=	_	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
91-6	14927-14929	42	_	_
91-7	14929-14930	)	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
91-8	14931-14938	HEALTHY	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
91-9	14939-14950	INDIVIDUALS	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
91-10	14951-14952	(	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
91-11	14952-14953	N	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
91-12	14954-14955	=	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
91-13	14956-14958	42	_	_
91-14	14958-14959	)	_	_
91-15	14960-14970	STATISTICS	_	_
91-16	14973-14979	Gender	_	_
91-17	14980-14982	12	_	_
91-18	14983-14990	females	_	_
91-19	14990-14991	,	_	_
91-20	14992-14994	30	_	_
91-21	14995-15000	males	_	_
91-22	15001-15003	16	_	_
91-23	15004-15011	females	_	_
91-24	15011-15012	,	_	_
91-25	15013-15015	26	_	_
91-26	15016-15021	males	_	_
91-27	15022-15024	χ2	_	_
91-28	15024-15025	(	_	_
91-29	15025-15026	1	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
91-30	15026-15027	)	_	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
91-31	15028-15029	=	_	_
91-32	15030-15034	.355	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
91-33	15034-15035	,	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
91-34	15036-15037	p	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
91-35	15038-15039	=	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
91-36	15040-15045	0.488	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
91-37	15048-15051	AGE	_	_
91-38	15052-15053	(	_	_
91-39	15053-15055	IN	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
91-40	15056-15061	YEARS	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_
91-41	15061-15062	)	_	_
91-42	15063-15067	35.1	_	_
91-43	15068-15069	(	_	_
91-44	15069-15070	±	_	_
91-45	15070-15073	7.4	_	_
91-46	15073-15074	)	_	_
91-47	15075-15079	33.5	_	_
91-48	15080-15081	(	_	_
91-49	15081-15082	±	_	_
91-50	15082-15085	7.8	_	_
91-51	15085-15086	)	_	_
91-52	15087-15088	t	_	_
91-53	15088-15089	(	_	_
91-54	15089-15091	82	_	_
91-55	15091-15092	)	_	_
91-56	15093-15094	=	_	_
91-57	15095-15096	1	_	_
91-58	15096-15097	,	_	_
91-59	15098-15099	p	_	_
91-60	15100-15101	=	_	_
91-61	15102-15107	0.321	_	_
91-62	15110-15116	VERBAL	_	_
91-63	15117-15119	IQ	_	_
91-64	15120-15123	101	_	_
91-65	15124-15125	(	_	_
91-66	15125-15126	±	_	_
91-67	15126-15129	9.4	_	_
91-68	15129-15130	)	_	_
91-69	15131-15136	104.9	_	_
91-70	15137-15138	(	_	_
91-71	15138-15139	±	_	_
91-72	15139-15142	9.4	_	_
91-73	15142-15143	)	_	_
91-74	15144-15145	t	_	_
91-75	15145-15146	(	_	_
91-76	15146-15148	78	_	_
91-77	15148-15149	)	_	_
91-78	15150-15151	=	_	_
91-79	15152-15156	2.13	_	_
91-80	15156-15157	,	_	_
91-81	15158-15159	p	_	_
91-82	15160-15161	=	_	_
91-83	15162-15167	0.036	_	_
91-84	15170-15173	EHI	_	_
91-85	15174-15178	67.4	_	_
91-86	15178-15179	(	_	_
91-87	15179-15180	±	_	_
91-88	15180-15182	53	_	_
91-89	15182-15183	)	_	_
91-90	15184-15189	69.72	_	_
91-91	15190-15191	(	_	_
91-92	15191-15192	±	_	_
91-93	15192-15197	48.09	_	_
91-94	15197-15198	)	_	_
91-95	15199-15200	t	_	_
91-96	15200-15201	(	_	_
91-97	15201-15203	77	_	_
91-98	15203-15204	)	_	_
91-99	15205-15206	=	_	_
91-100	15207-15210	.21	_	_
91-101	15210-15211	,	_	_
91-102	15212-15213	p	_	_
91-103	15214-15215	=	_	_
91-104	15216-15220	.837	_	_
91-105	15223-15231	DURATION	_	_
91-106	15232-15234	OF	_	_
91-107	15235-15242	ILLNESS	_	_
91-108	15243-15244	(	_	_
91-109	15244-15249	YEARS	_	_
91-110	15249-15250	)	_	_
91-111	15251-15254	9.4	_	_
91-112	15255-15256	(	_	_
91-113	15256-15257	±	_	_
91-114	15257-15258	6	_	_
91-115	15258-15259	)	_	_
91-116	15264-15267	AGE	_	_
91-117	15268-15270	OF	_	_
91-118	15271-15278	ILLNESS	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
91-119	15279-15284	ONSET	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
91-120	15285-15286	(	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
91-121	15286-15291	YEARS	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
91-122	15291-15292	)	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
91-123	15293-15297	25.9	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
91-124	15298-15299	(	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
91-125	15299-15300	±	_	_
91-126	15300-15303	7.1	_	_
91-127	15303-15304	)	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_
91-128	15309-15314	PANSS	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
91-129	15315-15323	POSITIVE	_	_
91-130	15324-15328	20.7	_	_
91-131	15329-15330	(	_	_
91-132	15330-15331	±	_	_
91-133	15331-15334	6.7	_	_
91-134	15334-15335	)	_	_
91-135	15340-15345	PANSS	_	_
91-136	15346-15354	NEGATIVE	_	_
91-137	15355-15359	22.6	_	_
91-138	15360-15361	(	_	_
91-139	15361-15362	±	_	_
91-140	15362-15365	7.6	_	_
91-141	15365-15366	)	_	_
91-142	15371-15376	PANSS	_	_
91-143	15377-15384	GENERAL	_	_
91-144	15385-15387	41	_	_
91-145	15388-15389	(	_	_
91-146	15389-15390	±	_	_
91-147	15390-15394	10.9	_	_
91-148	15394-15395	)	_	_
91-149	15400-15405	PANSS	_	_
91-150	15406-15411	TOTAL	_	_
91-151	15412-15416	84.5	_	_
91-152	15417-15418	(	_	_
91-153	15418-15419	±	_	_
91-154	15419-15423	21.5	_	_
91-155	15423-15424	)	_	_
91-156	15429-15433	SAPS	_	_
91-157	15434-15443	DELUSIONS	_	_
91-158	15444-15448	21.3	_	_
91-159	15449-15450	(	_	_
91-160	15450-15451	±	_	_
91-161	15451-15455	10.9	_	_
91-162	15455-15456	)	_	_
91-163	15461-15465	SANS	_	_
91-164	15466-15475	ANHEDONIA	_	_
91-165	15476-15480	12.4	_	_
91-166	15481-15482	(	_	_
91-167	15482-15483	±	_	_
91-168	15483-15486	4.9	_	_
91-169	15486-15487	)	_	_
91-170	15493-15501	Implicit	_	_
91-171	15502-15510	salience	_	_
91-172	15511-15519	paradigm	_	_
91-173	15520-15521	(	_	_
91-174	15521-15524	ISP	_	_
91-175	15524-15525	)	_	_
91-176	15526-15530	This	_	_
91-177	15531-15539	paradigm	_	_
91-178	15540-15543	was	_	_
91-179	15544-15554	explicitly	_	_
91-180	15555-15565	instructed	_	_
91-181	15566-15570	like	_	_
91-182	15571-15572	a	_	_
91-183	15573-15589	target-detection	_	_
91-184	15590-15594	task	_	_
91-185	15595-15601	though	_	_
91-186	15602-15612	implicitly	_	_
91-187	15613-15618	being	_	_
91-188	15619-15620	a	_	_
91-189	15621-15629	learning	_	_
91-190	15630-15638	paradigm	_	_
91-191	15639-15644	where	_	_
91-192	15645-15653	features	_	_
91-193	15654-15656	of	_	_
91-194	15657-15664	neutral	_	_
91-195	15665-15672	stimuli	_	_
91-196	15673-15682	predicted	_	_
91-197	15683-15690	certain	_	_
91-198	15691-15699	outcomes	_	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
91-199	15699-15700	.	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging

92-1	15701-15703	It	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
92-2	15704-15713	consisted	_	_
92-3	15714-15716	of	_	_
92-4	15717-15720	160	_	_
92-5	15721-15727	trials	_	_
92-6	15728-15733	where	_	_
92-7	15734-15742	subjects	_	_
92-8	15743-15747	were	_	_
92-9	15748-15752	told	_	_
92-10	15753-15755	to	_	_
92-11	15756-15768	discriminate	_	_
92-12	15769-15772	the	_	_
92-13	15773-15781	outcomes	_	_
92-14	15782-15783	(	_	_
92-15	15783-15785	10	_	_
92-16	15786-15794	Eurocent	_	_
92-17	15795-15799	coin	_	_
92-18	15800-15802	or	_	_
92-19	15803-15807	blue	_	_
92-20	15808-15814	circle	_	_
92-21	15814-15815	)	_	_
92-22	15816-15818	of	_	_
92-23	15819-15823	each	_	_
92-24	15824-15829	trial	_	_
92-25	15829-15830	.	_	_

93-1	15831-15840	Therefore	_	_
93-2	15840-15841	,	_	_
93-3	15842-15847	their	_	_
93-4	15848-15852	only	_	_
93-5	15853-15857	task	_	_
93-6	15858-15861	was	_	_
93-7	15862-15864	to	_	_
93-8	15865-15870	press	_	_
93-9	15871-15872	a	_	_
93-10	15873-15883	respective	_	_
93-11	15884-15890	button	_	_
93-12	15891-15895	when	_	_
93-13	15896-15900	they	_	_
93-14	15901-15904	saw	_	_
93-15	15905-15906	a	_	_
93-16	15907-15911	coin	_	_
93-17	15911-15912	,	_	_
93-18	15913-15919	versus	_	_
93-19	15920-15927	another	_	_
93-20	15928-15934	button	_	_
93-21	15935-15939	when	_	_
93-22	15940-15944	they	_	_
93-23	15945-15948	saw	_	_
93-24	15949-15952	the	_	_
93-25	15953-15957	blue	_	_
93-26	15958-15964	circle	_	_
93-27	15964-15965	.	_	_

94-1	15966-15974	Subjects	_	_
94-2	15975-15979	were	_	_
94-3	15980-15984	told	_	_
94-4	15985-15989	that	_	_
94-5	15990-15994	they	_	_
94-6	15995-16000	would	_	_
94-7	16001-16008	receive	_	_
94-8	16009-16012	the	_	_
94-9	16013-16019	amount	_	_
94-10	16020-16022	of	_	_
94-11	16023-16028	money	_	_
94-12	16029-16033	they	_	_
94-13	16034-16037	had	_	_
94-14	16038-16042	seen	_	_
94-15	16043-16049	during	_	_
94-16	16050-16053	the	_	_
94-17	16054-16058	task	_	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
94-18	16059-16071	irrespective	_	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
94-19	16072-16074	of	_	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
94-20	16075-16082	whether	_	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
94-21	16083-16087	they	_	_
94-22	16088-16091	had	_	_
94-23	16092-16099	pressed	_	_
94-24	16100-16101	a	_	_
94-25	16102-16108	button	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
94-26	16109-16111	or	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
94-27	16112-16115	not	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
94-28	16115-16116	,	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
94-29	16117-16123	though	_	_
94-30	16124-16128	they	_	_
94-31	16129-16133	were	_	_
94-32	16134-16144	encouraged	_	_
94-33	16145-16147	by	_	_
94-34	16148-16151	the	_	_
94-35	16152-16165	experimenters	_	_
94-36	16166-16169	not	_	_
94-37	16170-16172	to	_	_
94-38	16173-16177	miss	_	_
94-39	16178-16181	too	_	_
94-40	16182-16186	many	_	_
94-41	16187-16193	trials	_	_
94-42	16194-16201	because	_	_
94-43	16202-16206	this	_	_
94-44	16207-16212	would	_	_
94-45	16213-16219	impede	_	_
94-46	16220-16223	the	_	_
94-47	16224-16232	analysis	_	_
94-48	16232-16233	.	_	_

95-1	16234-16237	The	_	_
95-2	16238-16246	outcomes	_	_
95-3	16247-16251	were	_	_
95-4	16252-16260	preceded	_	_
95-5	16261-16263	by	_	_
95-6	16264-16275	conditioned	_	_
95-7	16276-16283	stimuli	_	_
95-8	16284-16288	that	_	_
95-9	16289-16297	differed	_	_
95-10	16298-16300	in	_	_
95-11	16301-16306	color	_	_
95-12	16307-16310	and	_	_
95-13	16311-16316	shape	_	_
95-14	16316-16317	:	_	_
95-15	16318-16322	gray	_	_
95-16	16323-16325	or	_	_
95-17	16326-16334	colorful	_	_
95-18	16335-16342	squares	_	_
95-19	16343-16345	or	_	_
95-20	16346-16355	triangles	_	_
95-21	16356-16357	(	_	_
95-22	16357-16360	see	_	_
95-23	16361-16364	Fig	_	_
95-24	16365-16367	1A	_	_
95-25	16368-16371	and	_	_
95-26	16372-16374	1B	_	_
95-27	16374-16375	)	_	_
95-28	16375-16376	.	_	_

96-1	16377-16383	During	_	_
96-2	16384-16387	the	_	_
96-3	16388-16400	instructions	_	_
96-4	16400-16401	,	_	_
96-5	16402-16410	subjects	_	_
96-6	16411-16415	were	_	_
96-7	16416-16420	told	_	_
96-8	16421-16424	not	_	_
96-9	16425-16427	to	_	_
96-10	16428-16431	pay	_	_
96-11	16432-16441	attention	_	_
96-12	16442-16444	to	_	_
96-13	16445-16450	these	_	_
96-14	16451-16458	stimuli	_	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
96-15	16459-16468	preceding	_	_
96-16	16469-16472	the	_	_
96-17	16473-16481	outcomes	_	_
96-18	16481-16482	.	_	_

97-1	16483-16490	However	_	_
97-2	16490-16491	,	_	_
97-3	16492-16497	prior	_	_
97-4	16498-16500	to	_	_
97-5	16501-16509	scanning	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
97-6	16509-16510	,	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol	_
97-7	16511-16523	participants	_	_
97-8	16524-16528	were	_	_
97-9	16529-16535	primed	_	_
97-10	16536-16540	with	_	_
97-11	16541-16544	the	_	_
97-12	16545-16553	stimulus	_	_
97-13	16554-16562	features	_	_
97-14	16563-16568	while	_	_
97-15	16569-16573	they	_	_
97-16	16574-16578	were	_	_
97-17	16579-16584	asked	_	_
97-18	16585-16587	to	_	_
97-19	16588-16592	name	_	_
97-20	16593-16596	the	_	_
97-21	16597-16602	color	_	_
97-22	16603-16606	and	_	_
97-23	16607-16610	the	_	_
97-24	16611-16616	shape	_	_
97-25	16617-16619	of	_	_
97-26	16620-16624	each	_	_
97-27	16625-16627	of	_	_
97-28	16628-16631	the	_	_
97-29	16632-16636	four	_	_
97-30	16637-16648	conditioned	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
97-31	16649-16656	stimuli	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
97-32	16656-16657	.	_	_

98-1	16658-16662	Then	_	_
98-2	16662-16663	,	_	_
98-3	16664-16668	they	_	_
98-4	16669-16678	practiced	_	_
98-5	16679-16682	the	_	_
98-6	16683-16690	outcome	_	_
98-7	16691-16700	detection	_	_
98-8	16701-16704	for	_	_
98-9	16705-16707	10	_	_
98-10	16708-16714	trials	_	_
98-11	16714-16715	.	_	_

99-1	16716-16718	In	_	_
99-2	16719-16723	this	_	_
99-3	16724-16732	practice	_	_
99-4	16733-16740	session	_	_
99-5	16740-16741	,	_	_
99-6	16742-16745	all	_	_
99-7	16746-16754	outcomes	_	_
99-8	16755-16759	were	_	_
99-9	16760-16768	preceded	_	_
99-10	16769-16771	by	_	_
99-11	16772-16773	a	_	_
99-12	16774-16782	stimulus	_	_
99-13	16783-16787	that	_	_
99-14	16788-16791	was	_	_
99-15	16792-16795	not	_	_
99-16	16796-16805	presented	_	_
99-17	16806-16812	during	_	_
99-18	16813-16816	the	_	_
99-19	16817-16821	main	_	_
99-20	16822-16832	experiment	_	_
99-21	16833-16835	in	_	_
99-22	16836-16839	the	_	_
99-23	16840-16847	scanner	_	_
99-24	16847-16848	.	_	_

100-1	16849-16851	In	_	_
100-2	16852-16855	the	_	_
100-3	16856-16860	main	_	_
100-4	16861-16871	experiment	_	_
100-5	16871-16872	,	_	_
100-6	16873-16876	the	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
100-7	16877-16888	conditioned	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
100-8	16889-16896	stimuli	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
100-9	16897-16906	predicted	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
100-10	16907-16910	the	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
100-11	16911-16918	outcome	_	_
100-12	16919-16924	types	_	_
100-13	16925-16927	in	_	_
100-14	16928-16929	a	_	_
100-15	16930-16943	probabilistic	_	_
100-16	16944-16950	manner	_	_
100-17	16951-16955	that	_	_
100-18	16956-16964	reversed	_	_
100-19	16965-16971	during	_	_
100-20	16972-16975	the	_	_
100-21	16976-16980	task	_	_
100-22	16980-16981	.	_	_

101-1	16982-16993	Importantly	_	_
101-2	16993-16994	,	_	_
101-3	16995-16999	only	_	_
101-4	17000-17003	one	_	_
101-5	17004-17012	stimulus	_	_
101-6	17013-17020	feature	_	_
101-7	17021-17029	reliably	_	_
101-8	17030-17039	predicted	_	_
101-9	17040-17043	the	_	_
101-10	17044-17051	outcome	_	_
101-11	17052-17053	(	_	_
101-12	17053-17055	eg	_	_
101-13	17055-17056	,	_	_
101-14	17057-17062	shape	_	_
101-15	17062-17063	)	_	_
101-16	17063-17064	.	_	_

102-1	17065-17068	For	_	_
102-2	17069-17077	instance	_	_
102-3	17077-17078	,	_	_
102-4	17079-17082	80%	_	_
102-5	17083-17085	of	_	_
102-6	17086-17089	all	_	_
102-7	17090-17099	triangles	_	_
102-8	17100-17104	were	_	_
102-9	17105-17113	followed	_	_
102-10	17114-17116	by	_	_
102-11	17117-17120	the	_	_
102-12	17121-17125	coin	_	_
102-13	17126-17127	(	_	_
102-14	17127-17130	20%	_	_
102-15	17131-17137	circle	_	_
102-16	17137-17138	)	_	_
102-17	17138-17139	,	_	_
102-18	17140-17143	and	_	_
102-19	17144-17147	80%	_	_
102-20	17148-17150	of	_	_
102-21	17151-17154	all	_	_
102-22	17155-17162	squares	_	_
102-23	17163-17167	were	_	_
102-24	17168-17176	followed	_	_
102-25	17177-17179	by	_	_
102-26	17180-17183	the	_	_
102-27	17184-17188	blue	_	_
102-28	17189-17195	circle	_	_
102-29	17196-17197	(	_	_
102-30	17197-17200	20%	_	_
102-31	17201-17205	coin	_	_
102-32	17205-17206	)	_	_
102-33	17206-17207	.	_	_

103-1	17208-17215	Whether	_	_
103-2	17216-17219	the	_	_
103-3	17220-17226	square	_	_
103-4	17227-17229	or	_	_
103-5	17230-17233	the	_	_
103-6	17234-17242	triangle	_	_
103-7	17243-17252	predicted	_	_
103-8	17253-17256	the	_	_
103-9	17257-17261	coin	_	_
103-10	17262-17270	reversed	_	_
103-11	17271-17276	every	_	_
103-12	17277-17279	20	_	_
103-13	17280-17286	trials	_	_
103-14	17286-17287	.	_	_

104-1	17288-17290	In	_	_
104-2	17291-17294	the	_	_
104-3	17295-17303	meantime	_	_
104-4	17303-17304	,	_	_
104-5	17305-17308	the	_	_
104-6	17309-17314	color	_	_
104-7	17315-17317	of	_	_
104-8	17318-17321	the	_	_
104-9	17322-17329	stimuli	_	_
104-10	17330-17333	was	_	_
104-11	17334-17344	irrelevant	_	_
104-12	17345-17347	in	_	_
104-13	17348-17358	predicting	_	_
104-14	17359-17362	the	_	_
104-15	17363-17370	outcome	_	_
104-16	17370-17371	;	_	_
104-17	17372-17380	colorful	_	_
104-18	17381-17384	and	_	_
104-19	17385-17389	gray	_	_
104-20	17390-17397	stimuli	_	_
104-21	17398-17402	were	_	_
104-22	17403-17410	equally	_	_
104-23	17411-17419	followed	_	_
104-24	17420-17422	by	_	_
104-25	17423-17428	coins	_	_
104-26	17429-17432	and	_	_
104-27	17433-17440	circles	_	_
104-28	17441-17442	(	_	_
104-29	17442-17445	50%	_	_
104-30	17446-17450	each	_	_
104-31	17450-17451	)	_	_
104-32	17451-17452	.	_	_

105-1	17453-17458	After	_	_
105-2	17459-17462	the	_	_
105-3	17463-17468	first	_	_
105-4	17469-17473	half	_	_
105-5	17474-17476	of	_	_
105-6	17477-17480	the	_	_
105-7	17481-17491	experiment	_	_
105-8	17492-17496	this	_	_
105-9	17497-17500	was	_	_
105-10	17501-17509	reversed	_	_
105-11	17509-17510	,	_	_
105-12	17511-17514	and	_	_
105-13	17515-17519	then	_	_
105-14	17520-17523	the	_	_
105-15	17524-17532	formerly	_	_
105-16	17533-17543	irrelevant	_	_
105-17	17544-17551	feature	_	_
105-18	17552-17553	(	_	_
105-19	17553-17557	here	_	_
105-20	17557-17558	:	_	_
105-21	17559-17564	shape	_	_
105-22	17564-17565	)	_	_
105-23	17566-17575	predicted	_	_
105-24	17576-17579	the	_	_
105-25	17580-17587	outcome	_	_
105-26	17587-17588	,	_	_
105-27	17589-17596	whereas	_	_
105-28	17597-17600	the	_	_
105-29	17601-17606	other	_	_
105-30	17607-17614	feature	_	_
105-31	17615-17621	turned	_	_
105-32	17622-17632	irrelevant	_	_
105-33	17633-17634	(	_	_
105-34	17634-17637	see	_	_
105-35	17638-17641	Fig	_	_
105-36	17642-17643	2	_	_
105-37	17643-17644	)	_	_
105-38	17644-17645	.	_	_

106-1	17646-17649	The	_	_
106-2	17650-17658	relevant	_	_
106-3	17659-17669	dimensions	_	_
106-4	17670-17674	were	_	_
106-5	17675-17690	counterbalanced	_	_
106-6	17691-17697	across	_	_
106-7	17698-17710	participants	_	_
106-8	17711-17714	and	_	_
106-9	17715-17720	coins	_	_
106-10	17721-17724	and	_	_
106-11	17725-17732	neutral	_	_
106-12	17733-17741	outcomes	_	_
106-13	17742-17746	were	_	_
106-14	17747-17751	each	_	_
106-15	17752-17761	displayed	_	_
106-16	17762-17764	in	_	_
106-17	17765-17768	50%	_	_
106-18	17769-17771	of	_	_
106-19	17772-17775	all	_	_
106-20	17776-17782	trials	_	_
106-21	17782-17783	.	_	_

107-1	17784-17786	In	_	_
107-2	17787-17792	total	_	_
107-3	17792-17793	,	_	_
107-4	17794-17797	the	_	_
107-5	17798-17808	experiment	_	_
107-6	17809-17815	lasted	_	_
107-7	17816-17818	15	_	_
107-8	17819-17826	minutes	_	_
107-9	17827-17830	and	_	_
107-10	17831-17835	took	_	_
107-11	17836-17841	place	_	_
107-12	17842-17848	during	_	_
107-13	17849-17853	fMRI	_	_
107-14	17854-17862	scanning	_	_
107-15	17862-17863	.	_	_

108-1	17864-17876	Participants	_	_
108-2	17877-17885	received	_	_
108-3	17886-17889	the	_	_
108-4	17890-17896	amount	_	_
108-5	17897-17899	of	_	_
108-6	17900-17905	coins	_	_
108-7	17906-17910	seen	_	_
108-8	17911-17913	in	_	_
108-9	17914-17917	the	_	_
108-10	17918-17928	experiment	_	_
108-11	17929-17930	(	_	_
108-12	17930-17931	8	_	_
108-13	17932-17936	Euro	_	_
108-14	17936-17937	)	_	_
108-15	17937-17938	.	_	_

109-1	17939-17940	(	_	_
109-2	17940-17941	A	_	_
109-3	17941-17942	)	_	_
109-4	17943-17952	Depiction	_	_
109-5	17953-17955	of	_	_
109-6	17956-17959	one	_	_
109-7	17960-17963	ISP	_	_
109-8	17964-17969	trial	_	_
109-9	17969-17970	.	_	_

110-1	17971-17983	Participants	_	_
110-2	17984-17987	see	_	_
110-3	17988-17991	one	_	_
110-4	17992-17994	of	_	_
110-5	17995-17999	four	_	_
110-6	18000-18004	cues	_	_
110-7	18005-18006	(	_	_
110-8	18006-18007	B	_	_
110-9	18007-18008	)	_	_
110-10	18009-18013	that	_	_
110-11	18014-18016	is	_	_
110-12	18017-18021	then	_	_
110-13	18022-18030	followed	_	_
110-14	18031-18033	by	_	_
110-15	18034-18040	either	_	_
110-16	18041-18042	a	_	_
110-17	18043-18047	coin	_	_
110-18	18048-18049	(	_	_
110-19	18049-18061	representing	_	_
110-20	18062-18068	reward	_	_
110-21	18068-18069	)	_	_
110-22	18070-18072	or	_	_
110-23	18073-18074	a	_	_
110-24	18075-18079	blue	_	_
110-25	18080-18086	circle	_	_
110-26	18087-18088	(	_	_
110-27	18088-18095	neutral	_	_
110-28	18096-18103	outcome	_	_
110-29	18103-18104	)	_	_
110-30	18104-18105	.	_	_

111-1	18106-18110	They	_	_
111-2	18111-18115	have	_	_
111-3	18116-18118	to	_	_
111-4	18119-18126	respond	_	_
111-5	18127-18129	to	_	_
111-6	18130-18134	each	_	_
111-7	18135-18142	outcome	_	_
111-8	18143-18146	via	_	_
111-9	18147-18148	a	_	_
111-10	18149-18159	respective	_	_
111-11	18160-18166	button	_	_
111-12	18167-18172	press	_	_
111-13	18172-18173	.	_	_

112-1	18174-18175	(	_	_
112-2	18175-18176	B	_	_
112-3	18176-18177	)	_	_
112-4	18178-18189	Conditioned	_	_
112-5	18190-18194	cues	_	_
112-6	18195-18202	varying	_	_
112-7	18203-18205	in	_	_
112-8	18206-18211	color	_	_
112-9	18212-18215	and	_	_
112-10	18216-18221	shape	_	_
112-11	18221-18222	.	_	_

113-1	18223-18224	(	_	_
113-2	18224-18225	C	_	_
113-3	18225-18226	)	_	_
113-4	18227-18230	Log	_	_
113-5	18231-18239	reaction	_	_
113-6	18240-18245	times	_	_
113-7	18246-18247	(	_	_
113-8	18247-18252	logRT	_	_
113-9	18252-18253	)	_	_
113-10	18254-18257	and	_	_
113-11	18258-18267	simulated	_	_
113-12	18268-18273	logRT	_	_
113-13	18274-18275	(	_	_
113-14	18275-18281	dashed	_	_
113-15	18282-18287	lines	_	_
113-16	18287-18288	,	_	_
113-17	18289-18294	based	_	_
113-18	18295-18297	on	_	_
113-19	18298-18301	the	_	_
113-20	18302-18306	best	_	_
113-21	18307-18312	model	_	_
113-22	18312-18313	)	_	_
113-23	18314-18317	for	_	_
113-24	18318-18322	coin	_	_
113-25	18323-18324	(	_	_
113-26	18324-18329	green	_	_
113-27	18329-18330	)	_	_
113-28	18331-18334	and	_	_
113-29	18335-18341	circle	_	_
113-30	18342-18343	(	_	_
113-31	18343-18349	orange	_	_
113-32	18349-18350	)	_	_
113-33	18351-18357	trials	_	_
113-34	18357-18358	.	_	_

114-1	18359-18367	Subjects	_	_
114-2	18368-18372	were	_	_
114-3	18373-18379	faster	_	_
114-4	18380-18382	in	_	_
114-5	18383-18387	coin	_	_
114-6	18388-18392	than	_	_
114-7	18393-18395	in	_	_
114-8	18396-18402	circle	_	_
114-9	18403-18409	trials	_	_
114-10	18410-18413	and	_	_
114-11	18414-18421	speeded	_	_
114-12	18422-18424	up	_	_
114-13	18425-18430	their	_	_
114-14	18431-18440	responses	_	_
114-15	18441-18445	over	_	_
114-16	18446-18449	the	_	_
114-17	18450-18456	course	_	_
114-18	18457-18459	of	_	_
114-19	18460-18464	each	_	_
114-20	18465-18470	block	_	_
114-21	18470-18471	.	_	_

115-1	18472-18477	These	_	_
115-2	18478-18485	effects	_	_
115-3	18486-18490	were	_	_
115-4	18491-18495	also	_	_
115-5	18496-18504	captured	_	_
115-6	18505-18507	by	_	_
115-7	18508-18511	the	_	_
115-8	18512-18516	best	_	_
115-9	18517-18524	fitting	_	_
115-10	18525-18530	model	_	_
115-11	18530-18531	.	_	_

116-1	18532-18537	Upper	_	_
116-2	18538-18542	plot	_	_
116-3	18542-18543	:	_	_
116-4	18544-18554	Underlying	_	_
116-5	18555-18559	task	_	_
116-6	18560-18573	contingencies	_	_
116-7	18574-18581	between	_	_
116-8	18582-18587	color	_	_
116-9	18588-18591	and	_	_
116-10	18592-18599	outcome	_	_
116-11	18600-18601	(	_	_
116-12	18601-18605	blue	_	_
116-13	18605-18606	)	_	_
116-14	18607-18610	and	_	_
116-15	18611-18616	shape	_	_
116-16	18617-18620	and	_	_
116-17	18621-18628	outcome	_	_
116-18	18629-18630	(	_	_
116-19	18630-18633	red	_	_
116-20	18633-18634	)	_	_
116-21	18634-18635	.	_	_

117-1	18636-18640	Note	_	_
117-2	18641-18645	that	_	_
117-3	18646-18649	the	_	_
117-4	18650-18659	direction	_	_
117-5	18660-18662	of	_	_
117-6	18663-18666	the	_	_
117-7	18667-18679	trajectories	_	_
117-8	18680-18688	reflects	_	_
117-9	18689-18690	a	_	_
117-10	18691-18699	tendency	_	_
117-11	18700-18707	towards	_	_
117-12	18708-18710	an	_	_
117-13	18711-18722	association	_	_
117-14	18723-18724	(	_	_
117-15	18724-18726	eg	_	_
117-16	18726-18727	,	_	_
117-17	18728-18729	1	_	_
117-18	18730-18733	for	_	_
117-19	18734-18735	[	_	_
117-20	18735-18743	triangle	_	_
117-21	18744-18745	→	_	_
117-22	18746-18752	reward	_	_
117-23	18752-18753	;	_	_
117-24	18754-18760	square	_	_
117-25	18761-18762	→	_	_
117-26	18762-18768	circle	_	_
117-27	18768-18769	]	_	_
117-28	18770-18773	and	_	_
117-29	18774-18775	0	_	_
117-30	18776-18779	for	_	_
117-31	18780-18783	the	_	_
117-32	18784-18792	opposite	_	_
117-33	18793-18805	associations	_	_
117-34	18805-18806	)	_	_
117-35	18807-18810	and	_	_
117-36	18811-18815	does	_	_
117-37	18816-18819	not	_	_
117-38	18820-18827	reflect	_	_
117-39	18828-18829	a	_	_
117-40	18830-18836	reward	_	_
117-41	18837-18842	value	_	_
117-42	18842-18843	.	_	_

118-1	18844-18846	In	_	_
118-2	18847-18851	this	_	_
118-3	18852-18859	example	_	_
118-4	18859-18860	,	_	_
118-5	18861-18867	during	_	_
118-6	18868-18871	the	_	_
118-7	18872-18877	first	_	_
118-8	18878-18882	half	_	_
118-9	18883-18885	of	_	_
118-10	18886-18889	the	_	_
118-11	18890-18893	ISP	_	_
118-12	18893-18894	,	_	_
118-13	18895-18900	color	_	_
118-14	18901-18903	is	_	_
118-15	18904-18912	relevant	_	_
118-16	18913-18916	for	_	_
118-17	18917-18927	predicting	_	_
118-18	18928-18931	the	_	_
118-19	18932-18939	outcome	_	_
118-20	18939-18940	,	_	_
118-21	18941-18948	whereas	_	_
118-22	18949-18952	the	_	_
118-23	18953-18960	squares	_	_
118-24	18961-18964	and	_	_
118-25	18965-18974	triangles	_	_
118-26	18975-18979	both	_	_
118-27	18980-18987	predict	_	_
118-28	18988-18992	coin	_	_
118-29	18993-18996	and	_	_
118-30	18997-19003	circle	_	_
118-31	19004-19008	with	_	_
118-32	19009-19010	a	_	_
118-33	19011-19022	probability	_	_
118-34	19023-19025	of	_	_
118-35	19026-19029	0.5	_	_
118-36	19030-19033	and	_	_
118-37	19034-19037	are	_	_
118-38	19038-19047	therefore	_	_
118-39	19048-19058	irrelevant	_	_
118-40	19058-19059	.	_	_

119-1	19060-19063	The	_	_
119-2	19064-19080	extradimensional	_	_
119-3	19081-19090	relevance	_	_
119-4	19091-19099	reverses	_	_
119-5	19100-19105	after	_	_
119-6	19106-19108	80	_	_
119-7	19109-19115	trials	_	_
119-8	19115-19116	,	_	_
119-9	19117-19120	and	_	_
119-10	19121-19126	shape	_	_
119-11	19127-19134	becomes	_	_
119-12	19135-19143	relevant	_	_
119-13	19143-19144	.	_	_

120-1	19145-19151	Inside	_	_
120-2	19152-19155	the	_	_
120-3	19156-19164	relevant	_	_
120-4	19165-19173	features	_	_
120-5	19173-19174	,	_	_
120-6	19175-19178	the	_	_
120-7	19179-19182	80%	_	_
120-8	19183-19191	rewarded	_	_
120-9	19192-19199	feature	_	_
120-10	19200-19213	manifestation	_	_
120-11	19214-19222	reverses	_	_
120-12	19223-19228	every	_	_
120-13	19229-19231	20	_	_
120-14	19232-19237	trial	_	_
120-15	19238-19243	block	_	_
120-16	19243-19244	.	_	_

121-1	19245-19249	That	_	_
121-2	19250-19252	is	_	_
121-3	19253-19255	to	_	_
121-4	19256-19259	say	_	_
121-5	19259-19260	,	_	_
121-6	19261-19263	if	_	_
121-7	19264-19272	colorful	_	_
121-8	19273-19277	cues	_	_
121-9	19278-19281	are	_	_
121-10	19282-19290	rewarded	_	_
121-11	19291-19293	in	_	_
121-12	19294-19297	80%	_	_
121-13	19298-19300	of	_	_
121-14	19301-19307	trials	_	_
121-15	19308-19309	(	_	_
121-16	19309-19313	gray	_	_
121-17	19314-19318	cues	_	_
121-18	19319-19321	in	_	_
121-19	19322-19325	20%	_	_
121-20	19325-19326	)	_	_
121-21	19327-19329	in	_	_
121-22	19330-19333	the	_	_
121-23	19334-19343	beginning	_	_
121-24	19343-19344	,	_	_
121-25	19345-19349	gray	_	_
121-26	19350-19354	cues	_	_
121-27	19355-19358	are	_	_
121-28	19359-19367	followed	_	_
121-29	19368-19370	by	_	_
121-30	19371-19376	coins	_	_
121-31	19377-19378	(	_	_
121-32	19378-19386	colorful	_	_
121-33	19387-19391	cues	_	_
121-34	19392-19394	by	_	_
121-35	19395-19396	a	_	_
121-36	19397-19403	circle	_	_
121-37	19403-19404	)	_	_
121-38	19405-19408	for	_	_
121-39	19409-19412	the	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
121-40	19413-19417	next	_	_
121-41	19418-19420	20	_	_
121-42	19421-19427	trials	_	_
121-43	19427-19428	.	_	_

122-1	19429-19435	Middle	_	_
122-2	19436-19440	plot	_	_
122-3	19440-19441	:	_	_
122-4	19442-19445	One	_	_
122-5	19446-19453	subject	_	_
122-6	19453-19454	’	_	_
122-7	19454-19455	s	_	_
122-8	19456-19466	individual	_	_
122-9	19467-19473	belief	_	_
122-10	19474-19486	trajectories	_	_
122-11	19487-19490	for	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
122-12	19491-19496	color	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
122-13	19497-19498	(	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
122-14	19498-19502	blue	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
122-15	19502-19503	)	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
122-16	19504-19507	and	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
122-17	19508-19513	shape	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
122-18	19514-19515	(	_	_
122-19	19515-19518	red	_	_
122-20	19518-19519	)	_	_
122-21	19520-19532	associations	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
122-22	19533-19537	with	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
122-23	19538-19545	outcome	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
122-24	19546-19551	based	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
122-25	19552-19554	on	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
122-26	19555-19558	the	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
122-27	19559-19563	best	_	_
122-28	19564-19571	fitting	_	_
122-29	19572-19577	model	_	_
122-30	19578-19579	(	_	_
122-31	19579-19583	2HGF	_	_
122-32	19584-19589	RelPE	_	_
122-33	19589-19590	+	_	_
122-34	19590-19599	IrrelBias	_	_
122-35	19599-19600	)	_	_
122-36	19600-19601	.	_	_

123-1	19602-19607	Lower	_	_
123-2	19608-19612	plot	_	_
123-3	19612-19613	:	_	_
123-4	19614-19626	Trajectories	_	_
123-5	19627-19631	that	_	_
123-6	19632-19636	were	_	_
123-7	19637-19641	used	_	_
123-8	19642-19644	to	_	_
123-9	19645-19654	determine	_	_
123-10	19655-19665	individual	_	_
123-11	19666-19674	reaction	_	_
123-12	19675-19680	times	_	_
123-13	19681-19683	in	_	_
123-14	19684-19687	the	_	_
123-15	19688-19692	best	_	_
123-16	19693-19701	response	_	_
123-17	19702-19707	model	_	_
123-18	19707-19708	:	_	_
123-19	19709-19717	Inferred	_	_
123-20	19718-19727	relevance	_	_
123-21	19728-19735	weights	_	_
123-22	19736-19737	(	_	_
123-23	19737-19740	see	_	_
123-24	19741-19743	Eq	_	_
123-25	19744-19745	5	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
123-26	19745-19746	)	_	_
123-27	19747-19750	for	_	_
123-28	19751-19756	color	_	_
123-29	19757-19758	(	_	_
123-30	19758-19762	blue	_	_
123-31	19762-19763	)	_	_
123-32	19764-19767	and	_	_
123-33	19768-19773	shape	_	_
123-34	19774-19775	(	_	_
123-35	19775-19778	red	_	_
123-36	19778-19779	)	_	_
123-37	19780-19791	predictions	_	_
123-38	19792-19795	and	_	_
123-39	19796-19799	the	_	_
123-40	19800-19804	mean	_	_
123-41	19805-19814	relevance	_	_
123-42	19815-19823	weighted	_	_
123-43	19824-19834	prediction	_	_
123-44	19835-19840	error	_	_
123-45	19841-19842	(	_	_
123-46	19842-19849	magenta	_	_
123-47	19849-19850	;	_	_
123-48	19851-19854	see	_	_
123-49	19855-19857	Eq	_	_
123-50	19858-19863	4.1.2	_	_
123-51	19863-19864	)	_	_
123-52	19864-19865	.	_	_

124-1	19866-19869	Raw	_	_
124-2	19870-19874	data	_	_
124-3	19875-19883	analysis	_	_
124-4	19884-19886	In	_	_
124-5	19887-19890	our	_	_
124-6	19891-19894	raw	_	_
124-7	19895-19899	data	_	_
124-8	19900-19908	analysis	_	_
124-9	19909-19911	of	_	_
124-10	19912-19920	reaction	_	_
124-11	19921-19926	times	_	_
124-12	19926-19927	,	_	_
124-13	19928-19930	we	_	_
124-14	19931-19938	focused	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
124-15	19939-19941	on	_	_
124-16	19942-19945	two	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
124-17	19946-19953	aspects	_	_
124-18	19953-19954	:	_	_
124-19	19955-19956	(	_	_
124-20	19956-19957	i	_	_
124-21	19957-19958	)	_	_
124-22	19959-19967	learning	_	_
124-23	19968-19970	of	_	_
124-24	19971-19974	the	_	_
124-25	19975-19984	regularly	_	_
124-26	19985-19994	reversing	_	_
124-27	19995-20003	relevant	_	_
124-28	20004-20011	feature	_	_
124-29	20012-20015	and	_	_
124-30	20016-20017	(	_	_
124-31	20017-20019	ii	_	_
124-32	20019-20020	)	_	_
124-33	20021-20029	aberrant	_	_
124-34	20030-20038	salience	_	_
124-35	20039-20046	towards	_	_
124-36	20047-20050	one	_	_
124-37	20051-20064	manifestation	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
124-38	20065-20067	of	_	_
124-39	20068-20071	the	_	_
124-40	20072-20082	irrelevant	_	_
124-41	20083-20090	feature	_	_
124-42	20090-20091	.	_	_

125-1	20092-20099	Extreme	_	_
125-2	20100-20108	reaction	_	_
125-3	20109-20114	times	_	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
125-4	20115-20116	(	_	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
125-5	20116-20117	<	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
125-6	20117-20120	150	_	_
125-7	20121-20123	ms	_	_
125-8	20124-20127	and	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
125-9	20128-20129	>	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
125-10	20129-20132	1.5	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
125-11	20133-20134	s	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
125-12	20134-20135	)	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
125-13	20136-20140	were	_	_
125-14	20141-20149	excluded	_	_
125-15	20149-20150	.	_	_

126-1	20151-20154	For	_	_
126-2	20155-20163	analyses	_	_
126-3	20164-20166	of	_	_
126-4	20167-20176	potential	_	_
126-5	20177-20185	learning	_	_
126-6	20185-20186	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
126-7	20187-20195	reaction	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
126-8	20196-20201	times	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
126-9	20202-20203	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
126-10	20203-20205	in	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
126-11	20206-20208	ms	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
126-12	20208-20209	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
126-13	20210-20214	were	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
126-14	20215-20218	log	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
126-15	20219-20230	transformed	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
126-16	20231-20233	to	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
126-17	20234-20241	achieve	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
126-18	20242-20248	normal	_	_
126-19	20249-20261	distribution	_	_
126-20	20262-20270	required	_	_
126-21	20271-20274	for	_	_
126-22	20275-20283	variance	_	_
126-23	20284-20292	analyses	_	_
126-24	20292-20293	.	_	_

127-1	20294-20299	First	_	_
127-2	20299-20300	,	_	_
127-3	20301-20303	we	_	_
127-4	20304-20310	tested	_	_
127-5	20311-20318	whether	_	_
127-6	20319-20327	subjects	_	_
127-7	20328-20335	learned	_	_
127-8	20336-20339	the	_	_
127-9	20340-20351	cue-outcome	_	_
127-10	20352-20365	contingencies	_	_
127-11	20366-20369	and	_	_
127-12	20370-20376	slowed	_	_
127-13	20377-20381	down	_	_
127-14	20382-20387	their	_	_
127-15	20388-20397	responses	_	_
127-16	20398-20400	if	_	_
127-17	20401-20404	the	_	_
127-18	20405-20412	outcome	_	_
127-19	20413-20418	could	_	_
127-20	20419-20422	not	_	_
127-21	20423-20425	be	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
127-22	20426-20435	predicted	_	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
127-23	20436-20441	based	_	_
127-24	20442-20444	on	_	_
127-25	20445-20448	the	_	_
127-26	20449-20458	preceding	_	_
127-27	20459-20463	cues	_	_
127-28	20464-20467	and	_	_
127-29	20468-20472	thus	_	_
127-30	20473-20481	violated	_	_
127-31	20482-20487	their	_	_
127-32	20488-20499	expectation	_	_
127-33	20499-20500	.	_	_

128-1	20501-20504	For	_	_
128-2	20505-20509	that	_	_
128-3	20509-20510	,	_	_
128-4	20511-20514	log	_	_
128-5	20515-20523	reaction	_	_
128-6	20524-20529	times	_	_
128-7	20530-20534	were	_	_
128-8	20535-20543	compared	_	_
128-9	20544-20547	for	_	_
128-10	20548-20556	expected	_	_
128-11	20557-20558	(	_	_
128-12	20558-20561	i.e	_	_
128-13	20561-20562	.	_	_
128-14	20563-20569	trials	_	_
128-15	20570-20574	when	_	_
128-16	20575-20578	the	_	_
128-17	20579-20582	0.8	_	_
128-18	20583-20591	rewarded	_	_
128-19	20592-20599	feature	_	_
128-20	20600-20603	was	_	_
128-21	20604-20612	followed	_	_
128-22	20613-20615	by	_	_
128-23	20616-20622	reward	_	_
128-24	20623-20626	and	_	_
128-25	20627-20633	trials	_	_
128-26	20634-20638	when	_	_
128-27	20639-20642	the	_	_
128-28	20643-20646	0.8	_	_
128-29	20647-20659	non-rewarded	_	_
128-30	20660-20667	feature	_	_
128-31	20668-20671	was	_	_
128-32	20672-20680	followed	_	_
128-33	20681-20683	by	_	_
128-34	20684-20685	a	_	_
128-35	20686-20692	circle	_	_
128-36	20692-20693	)	_	_
128-37	20694-20700	versus	_	_
128-38	20701-20711	unexpected	_	_
128-39	20712-20718	events	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
128-40	20719-20720	(	_	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
128-41	20720-20723	i.e	_	_
128-42	20723-20724	.	_	_
128-43	20725-20731	trials	_	_
128-44	20732-20736	when	_	_
128-45	20737-20740	the	_	_
128-46	20741-20744	0.8	_	_
128-47	20745-20753	rewarded	_	_
128-48	20754-20761	feature	_	_
128-49	20762-20765	was	_	_
128-50	20766-20774	followed	_	_
128-51	20775-20777	by	_	_
128-52	20778-20781	the	_	_
128-53	20782-20788	circle	_	_
128-54	20789-20792	and	_	_
128-55	20793-20799	trials	_	_
128-56	20800-20804	when	_	_
128-57	20805-20808	the	_	_
128-58	20809-20812	0.8	_	_
128-59	20813-20825	non-rewarded	_	_
128-60	20826-20833	feature	_	_
128-61	20834-20837	was	_	_
128-62	20838-20846	followed	_	_
128-63	20847-20849	by	_	_
128-64	20850-20851	a	_	_
128-65	20852-20856	coin	_	_
128-66	20856-20857	)	_	_
128-67	20858-20860	of	_	_
128-68	20861-20864	the	_	_
128-69	20865-20873	relevant	_	_
128-70	20874-20883	condition	_	_
128-71	20884-20886	in	_	_
128-72	20887-20888	a	_	_
128-73	20889-20906	repeated-measures	_	_
128-74	20907-20912	ANOVA	_	_
128-75	20913-20917	with	_	_
128-76	20918-20923	group	_	_
128-77	20924-20926	as	_	_
128-78	20927-20942	between-subject	_	_
128-79	20943-20949	factor	_	_
128-80	20950-20951	(	_	_
128-81	20951-20953	HC	_	_
128-82	20954-20960	versus	_	_
128-83	20961-20969	patients	_	_
128-84	20969-20970	)	_	_
128-85	20971-20974	and	_	_
128-86	20975-20980	event	_	_
128-87	20981-20985	type	_	_
128-88	20986-20988	as	_	_
128-89	20989-20995	within	_	_
128-90	20996-21002	factor	_	_
128-91	21003-21004	(	_	_
128-92	21004-21012	expected	_	_
128-93	21013-21019	versus	_	_
128-94	21020-21030	unexpected	_	_
128-95	21030-21031	)	_	_
128-96	21031-21032	.	_	_

129-1	21033-21039	Second	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#Thing
129-2	21039-21040	,	_	_
129-3	21041-21042	a	_	_
129-4	21043-21049	change	_	_
129-5	21050-21052	in	_	_
129-6	21053-21061	reaction	_	_
129-7	21062-21067	times	_	_
129-8	21068-21072	over	_	_
129-9	21073-21077	time	_	_
129-10	21078-21087	following	_	_
129-11	21088-21099	contingency	_	_
129-12	21100-21107	changes	_	_
129-13	21108-21114	inside	_	_
129-14	21115-21118	the	_	_
129-15	21119-21127	relevant	_	_
129-16	21128-21131	cue	_	_
129-17	21132-21139	feature	_	_
129-18	21140-21143	was	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	_
129-19	21144-21150	tested	_	_
129-20	21151-21156	using	_	_
129-21	21157-21158	a	_	_
129-22	21159-21176	repeated-measures	_	_
129-23	21177-21182	ANOVA	_	_
129-24	21182-21183	.	_	_

130-1	21184-21187	For	_	_
130-2	21188-21191	all	_	_
130-3	21192-21197	eight	_	_
130-4	21198-21204	blocks	_	_
130-5	21205-21209	with	_	_
130-6	21210-21212	20	_	_
130-7	21213-21219	trials	_	_
130-8	21220-21224	each	_	_
130-9	21224-21225	,	_	_
130-10	21226-21238	log-reaction	_	_
130-11	21239-21244	times	_	_
130-12	21245-21247	of	_	_
130-13	21248-21251	the	_	_
130-14	21252-21254	16	_	_
130-15	21255-21263	expected	_	_
130-16	21264-21270	events	_	_
130-17	21271-21272	(	_	_
130-18	21272-21274	ie	_	_
130-19	21274-21275	,	_	_
130-20	21276-21284	spanning	_	_
130-21	21285-21290	those	_	_
130-22	21291-21292	8	_	_
130-23	21293-21299	trials	_	_
130-24	21300-21304	when	_	_
130-25	21305-21308	the	_	_
130-26	21309-21317	rewarded	_	_
130-27	21318-21325	feature	_	_
130-28	21326-21329	was	_	_
130-29	21330-21338	followed	_	_
130-30	21339-21341	by	_	_
130-31	21342-21348	reward	_	_
130-32	21349-21352	and	_	_
130-33	21353-21356	the	_	_
130-34	21357-21358	8	_	_
130-35	21359-21365	trials	_	_
130-36	21366-21370	when	_	_
130-37	21371-21374	the	_	_
130-38	21375-21387	non-rewarded	_	_
130-39	21388-21395	feature	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
130-40	21396-21399	was	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
130-41	21400-21408	followed	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
130-42	21409-21411	by	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
130-43	21412-21413	a	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
130-44	21414-21420	circle	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
130-45	21420-21421	)	_	_
130-46	21422-21426	were	_	_
130-47	21427-21434	grouped	_	_
130-48	21435-21438	for	_	_
130-49	21439-21447	rewarded	_	_
130-50	21448-21454	versus	_	_
130-51	21455-21462	neutral	_	_
130-52	21463-21470	outcome	_	_
130-53	21471-21477	trials	_	_
130-54	21478-21479	(	_	_
130-55	21479-21488	Condition	_	_
130-56	21489-21495	factor	_	_
130-57	21495-21496	)	_	_
130-58	21497-21500	and	_	_
130-59	21501-21509	combined	_	_
130-60	21510-21514	into	_	_
130-61	21515-21516	4	_	_
130-62	21517-21521	time	_	_
130-63	21522-21526	bins	_	_
130-64	21527-21531	each	_	_
130-65	21531-21532	,	_	_
130-66	21533-21543	consisting	_	_
130-67	21544-21546	of	_	_
130-68	21547-21548	2	_	_
130-69	21549-21560	consecutive	_	_
130-70	21561-21567	trials	_	_
130-71	21568-21569	(	_	_
130-72	21569-21573	Time	_	_
130-73	21574-21580	factor	_	_
130-74	21580-21581	)	_	_
130-75	21581-21582	.	_	_

131-1	21583-21586	For	_	_
131-2	21587-21595	analyses	_	_
131-3	21596-21605	targeting	_	_
131-4	21606-21615	responses	_	_
131-5	21616-21620	with	_	_
131-6	21621-21627	regard	_	_
131-7	21628-21630	to	_	_
131-8	21631-21640	different	_	_
131-9	21641-21644	cue	_	_
131-10	21645-21653	features	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
131-11	21653-21654	,	_	_
131-12	21655-21661	please	_	_
131-13	21662-21665	see	_	_
131-14	21666-21669	the	_	_
131-15	21670-21680	Supplement	_	_
131-16	21680-21681	.	_	_

132-1	21682-21685	For	_	_
132-2	21686-21694	aberrant	_	_
132-3	21695-21703	salience	_	_
132-4	21704-21715	attribution	_	_
132-5	21715-21716	,	_	_
132-6	21717-21725	aberrant	_	_
132-7	21726-21734	salience	_	_
132-8	21735-21741	scores	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
132-9	21742-21746	were	_	_
132-10	21747-21757	calculated	_	_
132-11	21758-21760	as	_	_
132-12	21761-21763	in	_	_
132-13	21764-21767	the	_	_
132-14	21768-21776	previous	_	_
132-15	21777-21787	literature	_	_
132-16	21787-21788	,	_	_
132-17	21789-21792	and	_	_
132-18	21793-21802	reflected	_	_
132-19	21803-21805	an	_	_
132-20	21806-21816	individual	_	_
132-21	21817-21821	bias	_	_
132-22	21822-21829	towards	_	_
132-23	21830-21833	one	_	_
132-24	21834-21836	of	_	_
132-25	21837-21840	the	_	_
132-26	21841-21844	two	_	_
132-27	21845-21855	irrelevant	_	_
132-28	21856-21859	cue	_	_
132-29	21860-21874	manifestations	_	_
132-30	21875-21880	based	_	_
132-31	21881-21883	on	_	_
132-32	21884-21887	the	_	_
132-33	21888-21894	ground	_	_
132-34	21895-21900	truth	_	_
132-35	21901-21914	contingencies	_	_
132-36	21914-21915	.	_	_

133-1	21916-21919	For	_	_
133-2	21920-21924	that	_	_
133-3	21924-21925	,	_	_
133-4	21926-21929	the	_	_
133-5	21930-21934	mean	_	_
133-6	21935-21943	reaction	_	_
133-7	21944-21949	times	_	_
133-8	21950-21951	(	_	_
133-9	21951-21953	in	_	_
133-10	21954-21956	ms	_	_
133-11	21956-21957	)	_	_
133-12	21958-21960	to	_	_
133-13	21961-21965	each	_	_
133-14	21966-21968	of	_	_
133-15	21969-21972	the	_	_
133-16	21973-21977	four	_	_
133-17	21978-21981	cue	_	_
133-18	21982-21990	features	_	_
133-19	21991-21995	when	_	_
133-20	21996-22000	they	_	_
133-21	22001-22005	were	_	_
133-22	22006-22016	irrelevant	_	_
133-23	22017-22019	to	_	_
133-24	22020-22023	the	_	_
133-25	22024-22028	task	_	_
133-26	22029-22033	were	_	_
133-27	22034-22044	calculated	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
133-28	22044-22045	.	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale

134-1	22046-22050	Then	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
134-2	22050-22051	,	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
134-3	22052-22060	aberrant	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
134-4	22061-22069	salience	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
134-5	22070-22073	was	_	_
134-6	22074-22084	calculated	_	_
134-7	22085-22087	as	_	_
134-8	22088-22091	the	_	_
134-9	22092-22100	absolute	_	_
134-10	22101-22111	difference	_	_
134-11	22112-22114	in	_	_
134-12	22115-22123	reaction	_	_
134-13	22124-22129	times	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
134-14	22130-22137	between	_	_
134-15	22138-22142	both	_	_
134-16	22143-22157	manifestations	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
134-17	22158-22160	of	_	_
134-18	22161-22165	each	_	_
134-19	22166-22175	condition	_	_
134-20	22176-22177	(	_	_
134-21	22177-22179	eg	_	_
134-22	22179-22180	,	_	_
134-23	22181-22187	square	_	_
134-24	22188-22192	over	_	_
134-25	22193-22201	triangle	_	_
134-26	22202-22206	when	_	_
134-27	22207-22212	shape	_	_
134-28	22213-22215	is	_	_
134-29	22216-22226	irrelevant	_	_
134-30	22226-22227	)	_	_
134-31	22227-22228	.	_	_

135-1	22229-22233	Then	_	_
135-2	22233-22234	,	_	_
135-3	22235-22240	these	_	_
135-4	22241-22244	two	_	_
135-5	22245-22251	scores	_	_
135-6	22252-22256	were	_	_
135-7	22257-22266	collapsed	_	_
135-8	22267-22273	across	_	_
135-9	22274-22278	test	_	_
135-10	22279-22285	halves	_	_
135-11	22285-22286	.	_	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging

136-1	22287-22300	Computational	_	_
136-2	22301-22309	modeling	_	http://maven.renci.org/NeuroBridge/neurobridge#Pyromania
136-3	22310-22312	of	_	_
136-4	22313-22321	relevant	_	_
136-5	22322-22325	and	_	_
136-6	22326-22336	irrelevant	_	_
136-7	22337-22348	predictions	_	_
136-8	22349-22351	We	_	_
136-9	22352-22356	used	_	_
136-10	22357-22365	detailed	_	_
136-11	22366-22379	computational	_	_
136-12	22380-22388	modeling	_	_
136-13	22389-22397	combined	_	_
136-14	22398-22402	with	_	_
136-15	22403-22408	model	_	_
136-16	22409-22418	selection	_	_
136-17	22419-22421	in	_	_
136-18	22422-22427	order	_	_
136-19	22428-22430	to	_	_
136-20	22431-22437	assess	_	_
136-21	22438-22441	the	_	_
136-22	22442-22450	learning	_	_
136-23	22451-22461	mechanisms	_	_
136-24	22462-22469	driving	_	_
136-25	22470-22473	the	_	_
136-26	22474-22482	observed	_	_
136-27	22483-22493	individual	_	_
136-28	22494-22502	behavior	_	_
136-29	22502-22503	.	_	_

137-1	22504-22506	By	_	_
137-2	22507-22511	that	_	_
137-3	22512-22514	we	_	_
137-4	22515-22521	tested	_	_
137-5	22522-22524	if	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
137-6	22525-22533	subjects	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
137-7	22534-22541	learned	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
137-8	22542-22545	the	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
137-9	22546-22556	underlying	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
137-10	22557-22568	cue-outcome	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
137-11	22569-22581	associations	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
137-12	22582-22585	and	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
137-13	22586-22594	inferred	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
137-14	22595-22598	the	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
137-15	22599-22607	relevant	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
137-16	22608-22611	cue	_	_
137-17	22612-22619	feature	_	_
137-18	22619-22620	.	_	_

138-1	22621-22623	In	_	_
138-2	22624-22631	keeping	_	_
138-3	22632-22636	with	_	_
138-4	22637-22640	our	_	_
138-5	22641-22648	initial	_	_
138-6	22649-22659	definition	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
138-7	22660-22662	of	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
138-8	22663-22672	relevance	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
138-9	22672-22673	,	_	_
138-10	22674-22675	a	_	_
138-11	22676-22679	cue	_	_
138-12	22680-22687	feature	_	_
138-13	22688-22694	should	_	_
138-14	22695-22697	be	_	_
138-15	22698-22707	perceived	_	_
138-16	22708-22710	as	_	_
138-17	22711-22715	more	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
138-18	22716-22724	relevant	_	_
138-19	22725-22728	the	_	_
138-20	22729-22733	more	_	_
138-21	22734-22743	precisely	_	_
138-22	22744-22746	it	_	_
138-23	22747-22749	is	_	_
138-24	22750-22758	believed	_	_
138-25	22759-22761	to	_	_
138-26	22762-22769	predict	_	_
138-27	22770-22773	the	_	_
138-28	22774-22781	outcome	_	_
138-29	22781-22782	.	_	http://maven.renci.org/NeuroBridge/neurobridge#DissociativeDrugHarmfulUse

139-1	22783-22785	In	_	http://maven.renci.org/NeuroBridge/neurobridge#DissociativeDrugHarmfulUse
139-2	22786-22794	contrast	_	_
139-3	22794-22795	,	_	_
139-4	22796-22798	if	_	_
139-5	22799-22802	the	_	_
139-6	22803-22814	association	_	_
139-7	22815-22822	between	_	_
139-8	22823-22826	cue	_	_
139-9	22827-22834	feature	_	_
139-10	22835-22838	and	_	_
139-11	22839-22846	outcome	_	_
139-12	22847-22849	is	_	_
139-13	22850-22854	very	_	_
139-14	22855-22860	noisy	_	_
139-15	22860-22861	,	_	_
139-16	22862-22869	because	_	_
139-17	22870-22873	the	_	_
139-18	22874-22884	occurrence	_	_
139-19	22885-22887	of	_	_
139-20	22888-22894	reward	_	_
139-21	22895-22898	and	_	_
139-22	22899-22905	circle	_	_
139-23	22906-22909	are	_	_
139-24	22910-22917	equally	_	_
139-25	22918-22926	probable	_	_
139-26	22927-22931	this	_	_
139-27	22932-22939	feature	_	_
139-28	22940-22946	should	_	_
139-29	22947-22949	be	_	_
139-30	22950-22959	perceived	_	_
139-31	22960-22962	as	_	_
139-32	22963-22973	irrelevant	_	_
139-33	22973-22974	.	_	_

140-1	22975-22977	We	_	_
140-2	22978-22981	set	_	_
140-3	22982-22984	up	_	_
140-4	22985-22990	novel	_	_
140-5	22991-22999	response	_	_
140-6	23000-23006	models	_	_
140-7	23007-23011	that	_	_
140-8	23012-23022	postulated	_	_
140-9	23023-23030	slowing	_	_
140-10	23031-23035	down	_	_
140-11	23036-23038	of	_	_
140-12	23039-23048	responses	_	_
140-13	23049-23053	when	_	_
140-14	23054-23057	the	_	_
140-15	23058-23070	expectations	_	_
140-16	23071-23075	were	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
140-17	23076-23084	violated	_	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
140-18	23084-23085	.	_	_

141-1	23086-23101	Computationally	_	_
141-2	23101-23102	,	_	_
141-3	23103-23104	a	_	_
141-4	23105-23114	violation	_	_
141-5	23115-23118	was	_	_
141-6	23119-23127	captured	_	_
141-7	23128-23130	by	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
141-8	23131-23134	the	_	_
141-9	23135-23143	unsigned	_	_
141-10	23144-23146	PE	_	_
141-11	23147-23149	of	_	_
141-12	23150-23154	each	_	_
141-13	23155-23162	feature	_	_
141-14	23162-23163	.	_	_

142-1	23164-23166	In	_	_
142-2	23167-23176	different	_	_
142-3	23177-23183	models	_	_
142-4	23183-23184	,	_	_
142-5	23185-23187	we	_	_
142-6	23188-23196	compared	_	_
142-7	23197-23199	if	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_
142-8	23200-23208	unsigned	_	_
142-9	23209-23212	PEs	_	_
142-10	23213-23215	of	_	_
142-11	23216-23219	the	_	_
142-12	23220-23229	different	_	_
142-13	23230-23233	cue	_	_
142-14	23234-23242	features	_	_
142-15	23243-23257	differentially	_	_
142-16	23258-23266	affected	_	_
142-17	23267-23275	behavior	_	_
142-18	23276-23281	based	_	_
142-19	23282-23284	on	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
142-20	23285-23290	their	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
142-21	23291-23298	current	_	_
142-22	23299-23308	relevance	_	_
142-23	23308-23309	.	_	_

143-1	23310-23312	By	_	_
143-2	23313-23316	the	_	_
143-3	23317-23326	relevance	_	_
143-4	23327-23335	weighted	_	_
143-5	23336-23338	PE	_	_
143-6	23338-23339	,	_	_
143-7	23340-23342	we	_	_
143-8	23343-23354	implemented	_	_
143-9	23355-23364	increased	_	_
143-10	23365-23375	adaptation	_	_
143-11	23376-23378	to	_	_
143-12	23379-23389	surprising	_	_
143-13	23390-23396	events	_	_
143-14	23397-23398	(	_	_
143-15	23398-23406	unsigned	_	_
143-16	23407-23409	PE	_	_
143-17	23409-23410	)	_	_
143-18	23411-23420	predicted	_	_
143-19	23421-23423	by	_	_
143-20	23424-23427	the	_	_
143-21	23428-23432	most	_	_
143-22	23433-23441	relevant	_	_
143-23	23442-23445	cue	_	_
143-24	23446-23453	feature	_	_
143-25	23454-23456	as	_	_
143-26	23457-23461	well	_	_
143-27	23462-23464	as	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
143-28	23465-23474	decreased	_	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
143-29	23475-23485	adaptation	_	_
143-30	23486-23488	to	_	_
143-31	23489-23492	the	_	_
143-32	23493-23503	irrelevant	_	_
143-33	23504-23507	cue	_	_
143-34	23508-23515	feature	_	_
143-35	23515-23516	.	_	_

144-1	23517-23524	Thereby	_	_
144-2	23524-23525	,	_	_
144-3	23526-23528	we	_	_
144-4	23529-23535	tested	_	_
144-5	23536-23538	if	_	_
144-6	23539-23550	individuals	_	_
144-7	23551-23558	adapted	_	_
144-8	23559-23564	their	_	_
144-9	23565-23573	behavior	_	_
144-10	23574-23578	less	_	_
144-11	23579-23581	to	_	_
144-12	23582-23588	events	_	_
144-13	23589-23593	when	_	_
144-14	23594-23599	these	_	_
144-15	23600-23603	had	_	_
144-16	23604-23610	proven	_	_
144-17	23611-23613	to	_	_
144-18	23614-23616	be	_	_
144-19	23617-23622	noisy	_	_
144-20	23623-23626	and	_	_
144-21	23627-23640	uninformative	_	_
144-22	23641-23643	in	_	_
144-23	23644-23647	the	_	_
144-24	23648-23652	past	_	_
144-25	23652-23653	.	_	_

145-1	23654-23661	Instead	_	_
145-2	23661-23662	,	_	_
145-3	23663-23667	they	_	_
145-4	23668-23673	would	_	_
145-5	23674-23679	adapt	_	_
145-6	23680-23685	their	_	_
145-7	23686-23694	behavior	_	_
145-8	23695-23697	to	_	_
145-9	23698-23703	those	_	_
145-10	23704-23714	unexpected	_	_
145-11	23715-23721	events	_	_
145-12	23722-23726	that	_	_
145-13	23727-23731	were	_	_
145-14	23732-23736	held	_	_
145-15	23737-23739	to	_	_
145-16	23740-23742	be	_	_
145-17	23743-23754	informative	_	_
145-18	23755-23762	because	_	_
145-19	23763-23768	these	_	_
145-20	23769-23772	may	_	_
145-21	23773-23781	actually	_	_
145-22	23782-23788	signal	_	_
145-23	23789-23790	a	_	_
145-24	23791-23795	real	_	_
145-25	23796-23802	change	_	_
145-26	23803-23805	in	_	_
145-27	23806-23809	the	_	_
145-28	23810-23821	environment	_	_
145-29	23822-23823	(	_	_
145-30	23823-23825	as	_	_
145-31	23826-23829	the	_	_
145-32	23830-23841	contingency	_	_
145-33	23842-23849	changes	_	_
145-34	23850-23852	in	_	_
145-35	23853-23856	our	_	_
145-36	23857-23861	task	_	_
145-37	23861-23862	)	_	_
145-38	23862-23863	.	_	_

146-1	23864-23867	Our	_	_
146-2	23868-23876	modeling	_	_
146-3	23877-23885	analysis	_	_
146-4	23886-23889	was	_	_
146-5	23890-23896	guided	_	_
146-6	23897-23899	by	_	_
146-7	23900-23903	two	_	_
146-8	23904-23908	aims	_	_
146-9	23908-23909	:	_	_
146-10	23910-23918	Modeling	_	_
146-11	23919-23922	two	_	_
146-12	23923-23931	parallel	_	_
146-13	23932-23940	learning	_	_
146-14	23941-23950	processes	_	_
146-15	23951-23953	of	_	_
146-16	23954-23964	predicting	_	_
146-17	23965-23968	the	_	_
146-18	23969-23977	relevant	_	_
146-19	23978-23981	and	_	_
146-20	23982-23985	the	_	_
146-21	23986-23996	irrelevant	_	_
146-22	23997-24000	cue	_	_
146-23	24001-24008	feature	_	_
146-24	24009-24011	in	_	_
146-25	24012-24017	order	_	_
146-26	24018-24020	to	_	_
146-27	24021-24028	compute	_	_
146-28	24029-24037	distinct	_	_
146-29	24038-24048	prediction	_	_
146-30	24049-24054	error	_	_
146-31	24055-24067	trajectories	_	_
146-32	24068-24069	[	_	_
146-33	24069-24072	for	_	_
146-34	24073-24074	a	_	_
146-35	24075-24085	comparable	_	_
146-36	24086-24094	learning	_	_
146-37	24095-24100	model	_	_
146-38	24100-24101	,	_	_
146-39	24102-24108	please	_	_
146-40	24109-24112	see	_	_
146-41	24113-24114	]	_	_
146-42	24114-24115	.	_	_

147-1	24116-24120	Here	_	_
147-2	24120-24121	,	_	_
147-3	24122-24124	it	_	_
147-4	24125-24127	is	_	_
147-5	24128-24135	crucial	_	_
147-6	24136-24138	to	_	_
147-7	24139-24148	determine	_	_
147-8	24149-24150	a	_	_
147-9	24151-24157	formal	_	_
147-10	24158-24168	definition	_	_
147-11	24169-24171	of	_	_
147-12	24172-24173	“	_	_
147-13	24173-24182	relevance	_	_
147-14	24182-24183	”	_	_
147-15	24184-24189	since	_	_
147-16	24190-24193	the	_	_
147-17	24194-24206	participants	_	_
147-18	24207-24210	had	_	_
147-19	24211-24213	to	_	_
147-20	24214-24225	dynamically	_	_
147-21	24226-24231	infer	_	_
147-22	24232-24237	which	_	_
147-23	24238-24241	cue	_	_
147-24	24242-24249	feature	_	_
147-25	24250-24253	was	_	_
147-26	24254-24262	relevant	_	_
147-27	24263-24266	for	_	_
147-28	24267-24277	predicting	_	_
147-29	24278-24281	the	_	_
147-30	24282-24289	outcome	_	_
147-31	24290-24291	(	_	_
147-32	24291-24295	even	_	_
147-33	24296-24302	though	_	_
147-34	24303-24307	this	_	_
147-35	24308-24311	was	_	_
147-36	24312-24315	not	_	_
147-37	24316-24325	necessary	_	_
147-38	24326-24328	to	_	_
147-39	24329-24334	solve	_	_
147-40	24335-24338	the	_	_
147-41	24339-24343	task	_	_
147-42	24343-24344	,	_	_
147-43	24345-24349	that	_	_
147-44	24350-24352	is	_	_
147-45	24352-24353	,	_	_
147-46	24354-24368	discriminating	_	_
147-47	24369-24376	between	_	_
147-48	24377-24378	a	_	_
147-49	24379-24383	coin	_	_
147-50	24384-24387	and	_	_
147-51	24388-24389	a	_	_
147-52	24390-24396	circle	_	_
147-53	24396-24397	)	_	_
147-54	24397-24398	.	_	_

148-1	24399-24409	Describing	_	_
148-2	24410-24413	the	_	_
148-3	24414-24422	aberrant	_	_
148-4	24423-24431	salience	_	_
148-5	24432-24438	effect	_	_
148-6	24439-24441	to	_	_
148-7	24442-24444	an	_	_
148-8	24445-24455	irrelevant	_	_
148-9	24456-24463	feature	_	_
148-10	24464-24466	as	_	_
148-11	24467-24471	seen	_	_
148-12	24472-24474	in	_	_
148-13	24475-24483	previous	_	_
148-14	24484-24492	analyses	_	_
148-15	24493-24495	on	_	_
148-16	24496-24497	a	_	_
148-17	24498-24511	computational	_	_
148-18	24512-24517	level	_	_
148-19	24518-24520	by	_	_
148-20	24521-24528	finding	_	_
148-21	24529-24544	interindividual	_	_
148-22	24545-24556	differences	_	_
148-23	24557-24559	in	_	_
148-24	24560-24565	model	_	_
148-25	24566-24576	parameters	_	_
148-26	24577-24586	capturing	_	_
148-27	24587-24591	this	_	_
148-28	24592-24598	effect	_	_
148-29	24598-24599	.	_	_

149-1	24600-24602	We	_	_
149-2	24603-24610	modeled	_	_
149-3	24611-24622	predictions	_	_
149-4	24623-24626	for	_	_
149-5	24627-24631	each	_	_
149-6	24632-24634	of	_	_
149-7	24635-24638	the	_	_
149-8	24639-24642	two	_	_
149-9	24643-24646	cue	_	_
149-10	24647-24655	features	_	_
149-11	24655-24656	,	_	_
149-12	24657-24662	shape	_	_
149-13	24663-24666	and	_	_
149-14	24667-24672	color	_	_
149-15	24672-24673	,	_	_
149-16	24674-24676	in	_	_
149-17	24677-24685	separate	_	_
149-18	24686-24689	HGF	_	_
149-19	24690-24698	learning	_	_
149-20	24699-24705	models	_	_
149-21	24706-24708	so	_	_
149-22	24709-24713	that	_	_
149-23	24714-24715	a	_	_
149-24	24716-24730	trial-by-trial	_	_
149-25	24731-24742	expectation	_	_
149-26	24743-24746	was	_	_
149-27	24747-24755	computed	_	_
149-28	24756-24759	for	_	_
149-29	24760-24764	each	_	_
149-30	24765-24772	feature	_	_
149-31	24773-24774	(	_	_
149-32	24774-24782	learning	_	_
149-33	24783-24788	model	_	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
149-34	24788-24789	)	_	_
149-35	24789-24790	.	_	_

150-1	24791-24793	We	_	_
150-2	24794-24797	did	_	_
150-3	24798-24801	not	_	_
150-4	24802-24807	model	_	_
150-5	24808-24816	relevant	_	_
150-6	24817-24820	and	_	_
150-7	24821-24831	irrelevant	_	_
150-8	24832-24842	conditions	_	_
150-9	24843-24853	separately	_	_
150-10	24854-24861	because	_	_
150-11	24862-24864	of	_	_
150-12	24865-24868	two	_	_
150-13	24869-24876	reasons	_	_
150-14	24876-24877	.	_	_

151-1	24878-24883	First	_	_
151-2	24883-24884	,	_	_
151-3	24885-24888	the	_	_
151-4	24889-24899	generative	_	_
151-5	24900-24905	model	_	_
151-6	24906-24909	was	_	_
151-7	24910-24918	supposed	_	_
151-8	24919-24921	to	_	_
151-9	24922-24929	capture	_	_
151-10	24930-24933	the	_	_
151-11	24934-24942	subjects	_	_
151-12	24942-24943	’	_	_
151-13	24944-24952	learning	_	_
151-14	24953-24963	experience	_	_
151-15	24964-24967	and	_	_
151-16	24968-24972	they	_	_
151-17	24973-24977	were	_	_
151-18	24978-24981	not	_	_
151-19	24982-24992	instructed	_	_
151-20	24993-24998	about	_	_
151-21	24999-25002	the	_	_
151-22	25003-25007	task	_	_
151-23	25008-25017	structure	_	_
151-24	25018-25024	having	_	_
151-25	25025-25033	relevant	_	_
151-26	25034-25037	and	_	_
151-27	25038-25048	irrelevant	_	_
151-28	25049-25059	conditions	_	_
151-29	25059-25060	.	_	_

152-1	25061-25068	Instead	_	_
152-2	25069-25073	they	_	_
152-3	25074-25078	were	_	_
152-4	25079-25083	only	_	_
152-5	25084-25090	primed	_	_
152-6	25091-25095	with	_	_
152-7	25096-25099	the	_	_
152-8	25100-25111	distinction	_	_
152-9	25112-25114	by	_	_
152-10	25115-25122	feature	_	_
152-11	25122-25123	,	_	_
152-12	25124-25129	color	_	_
152-13	25130-25133	and	_	_
152-14	25134-25139	shape	_	_
152-15	25139-25140	,	_	_
152-16	25141-25143	in	_	_
152-17	25144-25147	the	_	_
152-18	25148-25156	practice	_	_
152-19	25157-25164	session	_	_
152-20	25164-25165	.	_	_

153-1	25166-25172	Second	_	_
153-2	25172-25173	,	_	_
153-3	25174-25179	after	_	_
153-4	25180-25183	the	_	_
153-5	25184-25189	first	_	_
153-6	25190-25194	half	_	_
153-7	25195-25197	of	_	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
153-8	25198-25201	the	_	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
153-9	25202-25212	experiment	_	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
153-10	25213-25215	we	_	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
153-11	25216-25224	switched	_	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
153-12	25225-25228	the	_	_
153-13	25229-25237	relevant	_	http://maven.renci.org/NeuroBridge/neurobridge#Pyromania
153-14	25238-25247	dimension	_	_
153-15	25248-25249	(	_	_
153-16	25249-25252	e.g	_	_
153-17	25252-25253	.	_	_
153-18	25254-25259	shape	_	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
153-19	25260-25262	to	_	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
153-20	25263-25268	color	_	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
153-21	25268-25269	)	_	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
153-22	25269-25270	.	_	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders

154-1	25271-25276	Hence	_	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
154-2	25276-25277	,	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
154-3	25278-25286	modeling	_	_
154-4	25287-25297	separately	_	_
154-5	25298-25301	for	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#Thing
154-6	25302-25311	relevance	_	_
154-7	25312-25318	versus	_	_
154-8	25319-25330	irrelevance	_	_
154-9	25331-25336	would	_	_
154-10	25337-25341	have	_	_
154-11	25342-25352	introduced	_	_
154-12	25353-25361	external	_	_
154-13	25362-25373	information	_	_
154-14	25374-25376	on	_	_
154-15	25377-25380	the	_	_
154-16	25381-25385	task	_	_
154-17	25386-25395	structure	_	_
154-18	25396-25400	that	_	_
154-19	25401-25404	was	_	_
154-20	25405-25408	not	_	_
154-21	25409-25419	accessible	_	_
154-22	25420-25422	to	_	_
154-23	25423-25431	subjects	_	_
154-24	25432-25435	and	_	_
154-25	25436-25440	thus	_	_
154-26	25441-25444	not	_	_
154-27	25445-25455	generative	_	_
154-28	25455-25456	.	_	_

155-1	25457-25460	The	_	_
155-2	25461-25470	resulting	_	_
155-3	25471-25479	learning	_	_
155-4	25480-25492	trajectories	_	_
155-5	25493-25496	for	_	_
155-6	25497-25502	shape	_	_
155-7	25503-25506	and	_	_
155-8	25507-25512	color	_	_
155-9	25513-25517	were	_	_
155-10	25518-25529	transformed	_	_
155-11	25530-25534	into	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
155-12	25535-25549	trial-by-trial	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
155-13	25550-25560	predictors	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
155-14	25561-25563	of	_	_
155-15	25564-25572	reaction	_	_
155-16	25573-25578	times	_	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
155-17	25579-25580	(	_	_
155-18	25580-25588	response	_	_
155-19	25589-25594	model	_	_
155-20	25594-25595	)	_	_
155-21	25595-25596	.	_	_

156-1	25597-25609	Hierarchical	_	_
156-2	25610-25618	Gaussian	_	_
156-3	25619-25625	filter	_	_
156-4	25626-25627	[	_	_
156-5	25627-25630	HGF	_	_
156-6	25630-25631	;	_	_
156-7	25632-25633	]	_	_
156-8	25634-25643	According	_	_
156-9	25644-25646	to	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
156-10	25647-25650	the	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
156-11	25651-25652	‘	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
156-12	25652-25660	Bayesian	_	_
156-13	25661-25666	brain	_	_
156-14	25666-25667	’	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
156-15	25668-25678	hypothesis	_	_
156-16	25678-25679	,	_	_
156-17	25680-25682	an	_	_
156-18	25683-25688	agent	_	_
156-19	25689-25694	forms	_	_
156-20	25695-25696	a	_	_
156-21	25697-25707	generative	_	http://maven.renci.org/NeuroBridge/neurobridge#Thing
156-22	25708-25713	model	_	_
156-23	25714-25716	of	_	_
156-24	25717-25720	the	_	_
156-25	25721-25726	world	_	_
156-26	25727-25729	in	_	_
156-27	25730-25734	part	_	_
156-28	25735-25737	by	_	_
156-29	25738-25748	increasing	_	_
156-30	25749-25752	the	_	_
156-31	25753-25762	precision	_	_
156-32	25763-25765	of	_	_
156-33	25766-25777	predictions	_	_
156-34	25778-25779	(	_	_
156-35	25779-25780	μ	_	_
156-36	25780-25781	)	_	_
156-37	25782-25784	to	_	_
156-38	25785-25797	successfully	_	_
156-39	25798-25803	adapt	_	_
156-40	25804-25807	one	_	_
156-41	25807-25808	’	_	_
156-42	25808-25809	s	_	_
156-43	25810-25818	behavior	_	_
156-44	25818-25819	.	_	_

157-1	25820-25823	The	_	_
157-2	25824-25827	HGF	_	_
157-3	25828-25834	offers	_	_
157-4	25835-25836	a	_	_
157-5	25837-25844	generic	_	_
157-6	25845-25854	framework	_	_
157-7	25855-25858	for	_	_
157-8	25859-25867	Bayesian	_	_
157-9	25868-25876	learning	_	_
157-10	25877-25879	on	_	_
157-11	25880-25888	multiple	_	_
157-12	25889-25901	hierarchical	_	_
157-13	25902-25908	levels	_	_
157-14	25908-25909	.	_	_

158-1	25910-25919	Crucially	_	_
158-2	25919-25920	,	_	_
158-3	25921-25924	the	_	_
158-4	25925-25931	belief	_	_
158-5	25932-25938	update	_	_
158-6	25939-25941	at	_	_
158-7	25942-25946	each	_	_
158-8	25947-25952	level	_	_
158-9	25953-25955	is	_	_
158-10	25956-25965	comprised	_	_
158-11	25966-25968	of	_	_
158-12	25969-25970	a	_	_
158-13	25971-25982	lower-level	_	_
158-14	25983-25993	prediction	_	_
158-15	25994-25999	error	_	_
158-16	26001-26005	that	_	_
158-17	26006-26008	is	_	_
158-18	26009-26017	weighted	_	_
158-19	26018-26027	according	_	_
158-20	26028-26030	to	_	http://maven.renci.org/NeuroBridge/neurobridge#StudySubject
158-21	26031-26032	a	_	_
158-22	26033-26044	cross-level	_	_
158-23	26045-26054	precision	_	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
158-24	26055-26060	ratio	_	_
158-25	26061-26062	(	_	_
158-26	26062-26065	Eqs	_	_
158-27	26066-26067	1	_	_
158-28	26068-26071	and	_	_
158-29	26072-26073	2	_	_
158-30	26073-26074	;	_	_
158-31	26075-26076	i	_	_
158-32	26077-26080	for	_	http://maven.renci.org/NeuroBridge/neurobridge#StudySubject
158-33	26081-26089	learning	_	_
158-34	26090-26095	level	_	_
158-35	26095-26096	,	_	http://maven.renci.org/NeuroBridge/neurobridge#PolysubstanceDependence
158-36	26097-26100	and	_	_
158-37	26101-26102	k	_	_
158-38	26103-26106	for	_	_
158-39	26107-26112	trial	_	_
158-40	26113-26119	number	_	_
158-41	26119-26120	)	_	_
158-42	26120-26121	.	_	_

159-1	26122-26125	The	_	_
159-2	26126-26135	precision	_	_
159-3	26136-26138	of	_	_
159-4	26139-26143	each	_	_
159-5	26144-26149	level	_	_
159-6	26149-26150	’	_	_
159-7	26150-26151	s	_	_
159-8	26152-26162	prediction	_	_
159-9	26164-26166	is	_	_
159-10	26167-26174	defined	_	_
159-11	26175-26177	as	_	_
159-12	26178-26181	the	_	_
159-13	26182-26189	inverse	_	_
159-14	26190-26198	variance	_	_
159-15	26199-26201	of	_	http://maven.renci.org/NeuroBridge/neurobridge#Age
159-16	26202-26205	the	_	_
159-17	26206-26216	prediction	_	_
159-18	26216-26217	.	_	_

160-1	26218-26220	We	_	_
160-2	26221-26225	used	_	_
160-3	26226-26227	a	_	_
160-4	26228-26229	“	_	_
160-5	26229-26232	two	_	_
160-6	26233-26241	branches	_	_
160-7	26241-26242	”	_	_
160-8	26243-26250	version	_	_
160-9	26251-26253	of	_	_
160-10	26254-26257	the	_	_
160-11	26258-26261	HGF	_	_
160-12	26262-26265	for	_	_
160-13	26266-26274	parallel	_	_
160-14	26275-26283	learning	_	_
160-15	26284-26286	of	_	_
160-16	26287-26290	the	_	_
160-17	26291-26296	shape	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
160-18	26297-26300	and	_	_
160-19	26301-26306	color	_	_
160-20	26307-26319	associations	_	_
160-21	26320-26324	with	_	_
160-22	26325-26328	the	_	_
160-23	26329-26336	outcome	_	_
160-24	26336-26337	.	_	_

161-1	26338-26340	In	_	_
161-2	26341-26344	our	_	_
161-3	26345-26354	modelling	_	_
161-4	26354-26355	,	_	_
161-5	26356-26358	we	_	_
161-6	26359-26366	focused	_	_
161-7	26367-26369	on	_	http://maven.renci.org/NeuroBridge/neurobridge#Thing
161-8	26370-26373	the	_	_
161-9	26374-26385	reliability	_	_
161-10	26386-26389	and	_	_
161-11	26390-26394	thus	_	_
161-12	26395-26405	undirected	_	_
161-13	26406-26413	beliefs	_	_
161-14	26414-26419	about	_	_
161-15	26420-26432	associations	_	_
161-16	26432-26433	.	_	_

162-1	26434-26438	Thus	_	_
162-2	26438-26439	,	_	_
162-3	26440-26443	the	_	_
162-4	26444-26453	direction	_	_
162-5	26454-26456	of	_	_
162-6	26457-26460	the	_	_
162-7	26461-26469	learning	_	_
162-8	26470-26482	trajectories	_	_
162-9	26483-26484	(	_	_
162-10	26484-26495	association	_	_
162-11	26496-26503	beliefs	_	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
162-12	26505-26508	and	_	_
162-13	26509-26519	prediction	_	_
162-14	26520-26526	errors	_	_
162-15	26527-26528	δ	_	_
162-16	26528-26529	)	_	_
162-17	26530-26533	did	_	_
162-18	26534-26537	not	_	_
162-19	26538-26545	reflect	_	_
162-20	26546-26549	the	_	_
162-21	26550-26556	reward	_	_
162-22	26557-26562	value	_	_
162-23	26563-26566	but	_	_
162-24	26567-26569	an	_	_
162-25	26570-26581	arbitrarily	_	_
162-26	26582-26592	determined	_	_
162-27	26593-26605	relationship	_	_
162-28	26606-26613	between	_	_
162-29	26614-26617	cue	_	_
162-30	26618-26625	feature	_	_
162-31	26626-26640	manifestations	_	_
162-32	26641-26644	and	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
162-33	26645-26653	outcomes	_	_
162-34	26653-26654	.	_	_

163-1	26655-26656	A	_	_
163-2	26657-26661	more	_	_
163-3	26662-26670	detailed	_	_
163-4	26671-26682	description	_	_
163-5	26683-26685	of	_	_
163-6	26686-26689	the	_	_
163-7	26690-26693	HGF	_	_
163-8	26694-26697	and	_	_
163-9	26698-26701	its	_	_
163-10	26702-26708	levels	_	_
163-11	26709-26712	can	_	_
163-12	26713-26715	be	_	_
163-13	26716-26721	found	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
163-14	26722-26724	in	_	_
163-15	26725-26728	the	_	_
163-16	26729-26739	Supplement	_	_
163-17	26739-26740	.	_	_

164-1	26741-26742	A	_	_
164-2	26743-26748	novel	_	_
164-3	26749-26759	definition	_	_
164-4	26760-26762	of	_	_
164-5	26763-26772	relevance	_	_
164-6	26772-26773	:	_	_
164-7	26774-26785	First-level	_	_
164-8	26786-26795	precision	_	_
164-9	26796-26801	Since	_	_
164-10	26802-26805	the	_	_
164-11	26806-26810	core	_	_
164-12	26811-26814	aim	_	_
164-13	26815-26817	of	_	_
164-14	26818-26822	this	_	_
164-15	26823-26828	study	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
164-16	26829-26832	was	_	_
164-17	26833-26836	the	_	_
164-18	26837-26849	dissociation	_	_
164-19	26850-26857	between	_	_
164-20	26858-26866	learning	_	_
164-21	26867-26872	about	_	_
164-22	26873-26881	relevant	_	_
164-23	26882-26888	versus	_	_
164-24	26889-26899	irrelevant	_	_
164-25	26900-26903	cue	_	_
164-26	26904-26912	features	_	_
164-27	26912-26913	,	_	_
164-28	26914-26917	the	_	_
164-29	26918-26922	term	_	_
164-30	26923-26932	relevance	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
164-31	26933-26938	needs	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
164-32	26939-26941	to	_	_
164-33	26942-26944	be	_	_
164-34	26945-26952	defined	_	_
164-35	26953-26961	formally	_	_
164-36	26961-26962	.	_	_

165-1	26963-26965	In	_	_
165-2	26966-26971	terms	_	_
165-3	26972-26974	of	_	_
165-4	26975-26978	the	_	_
165-5	26979-26982	ISP	_	_
165-6	26982-26983	,	_	_
165-7	26984-26985	a	_	_
165-8	26986-26989	cue	_	_
165-9	26990-26997	feature	_	_
165-10	26998-27004	should	_	_
165-11	27005-27007	be	_	_
165-12	27008-27017	perceived	_	_
165-13	27018-27020	as	_	_
165-14	27021-27025	more	_	_
165-15	27026-27034	relevant	_	_
165-16	27035-27038	the	_	_
165-17	27039-27043	more	_	_
165-18	27044-27053	precisely	_	_
165-19	27054-27056	it	_	_
165-20	27057-27059	is	_	_
165-21	27060-27068	believed	_	_
165-22	27069-27071	to	_	_
165-23	27072-27079	predict	_	_
165-24	27080-27083	the	_	_
165-25	27084-27091	outcome	_	_
165-26	27091-27092	.	_	_

166-1	27093-27095	In	_	_
166-2	27096-27104	contrast	_	_
166-3	27104-27105	,	_	_
166-4	27106-27108	if	_	_
166-5	27109-27112	the	_	_
166-6	27113-27119	belief	_	_
166-7	27121-27123	of	_	_
166-8	27124-27126	an	_	_
166-9	27127-27138	association	_	_
166-10	27139-27141	is	_	_
166-11	27142-27145	0.5	_	_
166-12	27146-27148	it	_	_
166-13	27149-27155	should	_	_
166-14	27156-27158	be	_	_
166-15	27159-27168	perceived	_	_
166-16	27169-27171	as	_	_
166-17	27172-27182	irrelevant	_	_
166-18	27183-27186	for	_	_
166-19	27187-27194	outcome	_	_
166-20	27195-27205	prediction	_	_
166-21	27206-27207	(	_	_
166-22	27207-27214	because	_	_
166-23	27215-27217	in	_	_
166-24	27218-27222	this	_	_
166-25	27223-27227	case	_	_
166-26	27228-27234	reward	_	_
166-27	27235-27238	and	_	_
166-28	27239-27245	circle	_	_
166-29	27246-27250	will	_	_
166-30	27251-27256	occur	_	_
166-31	27257-27261	with	_	_
166-32	27262-27265	the	_	_
166-33	27266-27270	same	_	_
166-34	27271-27282	probability	_	_
166-35	27283-27286	and	_	_
166-36	27287-27293	cannot	_	_
166-37	27294-27296	be	_	_
166-38	27297-27305	reliably	_	_
166-39	27306-27315	predicted	_	_
166-40	27315-27316	)	_	_
166-41	27316-27317	.	_	_

167-1	27318-27320	In	_	_
167-2	27321-27324	the	_	_
167-3	27325-27328	HGF	_	_
167-4	27329-27338	framework	_	_
167-5	27338-27339	,	_	_
167-6	27340-27344	this	_	_
167-7	27345-27359	interpretation	_	_
167-8	27360-27362	of	_	_
167-9	27363-27372	relevance	_	_
167-10	27373-27375	is	_	_
167-11	27376-27385	reflected	_	_
167-12	27386-27388	in	_	_
167-13	27389-27392	the	_	_
167-14	27393-27402	estimated	_	_
167-15	27403-27412	precision	_	_
167-16	27413-27415	of	_	_
167-17	27416-27426	prediction	_	_
167-18	27427-27429	on	_	_
167-19	27430-27433	the	_	_
167-20	27434-27439	first	_	_
167-21	27440-27445	level	_	_
167-22	27447-27448	(	_	_
167-23	27448-27451	see	_	_
167-24	27452-27453	4	_	_
167-25	27453-27454	)	_	_
167-26	27454-27455	.	_	_

168-1	27456-27458	It	_	_
168-2	27459-27461	is	_	_
168-3	27462-27463	a	_	_
168-4	27464-27472	function	_	_
168-5	27473-27477	only	_	_
168-6	27478-27480	of	_	_
168-7	27481-27484	the	_	_
168-8	27485-27496	first-level	_	_
168-9	27497-27508	association	_	_
168-10	27509-27519	prediction	_	_
168-11	27520-27521	,	_	_
168-12	27522-27527	which	_	_
168-13	27528-27534	ranges	_	_
168-14	27535-27542	between	_	_
168-15	27543-27544	0	_	_
168-16	27545-27548	and	_	_
168-17	27549-27550	1	_	_
168-18	27550-27551	.	_	_

169-1	27553-27556	has	_	_
169-2	27557-27558	a	_	_
169-3	27559-27566	minimum	_	_
169-4	27567-27569	of	_	_
169-5	27570-27571	4	_	_
169-6	27572-27575	for	_	_
169-7	27577-27580	and	_	_
169-8	27581-27590	increases	_	_
169-9	27591-27604	symmetrically	_	_
169-10	27605-27607	to	_	_
169-11	27608-27616	infinity	_	_
169-12	27617-27619	as	_	_
169-13	27621-27631	approaches	_	_
169-14	27632-27633	0	_	_
169-15	27634-27636	or	_	_
169-16	27637-27638	1	_	_
169-17	27638-27639	.	_	_

170-1	27640-27644	This	_	_
170-2	27645-27654	relevance	_	_
170-3	27655-27660	could	_	_
170-4	27661-27667	affect	_	_
170-5	27668-27671	how	_	_
170-6	27672-27679	beliefs	_	_
170-7	27680-27683	are	_	_
170-8	27684-27691	updated	_	_
170-9	27692-27693	(	_	_
170-10	27693-27696	for	_	_
170-11	27697-27701	this	_	_
170-12	27702-27716	implementation	_	_
170-13	27717-27718	(	_	_
170-14	27718-27719	‘	_	_
170-15	27719-27728	precision	_	_
170-16	27729-27737	feedback	_	_
170-17	27737-27738	’	_	_
170-18	27738-27739	)	_	_
170-19	27739-27740	,	_	_
170-20	27741-27744	see	_	_
170-21	27745-27748	the	_	_
170-22	27749-27759	Supplement	_	_
170-23	27759-27760	)	_	_
170-24	27761-27764	and	_	_
170-25	27764-27765	/	_	_
170-26	27765-27767	or	_	_
170-27	27768-27771	how	_	_
170-28	27772-27780	learning	_	_
170-29	27781-27788	signals	_	_
170-30	27789-27795	affect	_	_
170-31	27796-27804	behavior	_	_
170-32	27804-27805	,	_	_
170-33	27806-27811	which	_	_
170-34	27812-27814	we	_	_
170-35	27815-27826	implemented	_	_
170-36	27827-27829	in	_	_
170-37	27830-27834	four	_	_
170-38	27835-27843	response	_	_
170-39	27844-27850	models	_	_
170-40	27850-27851	.	_	_

171-1	27852-27855	Our	_	_
171-2	27856-27864	learning	_	_
171-3	27865-27870	model	_	_
171-4	27871-27876	space	_	_
171-5	27877-27886	contained	_	_
171-6	27887-27888	2	_	_
171-7	27888-27889	-	_	_
171-8	27889-27894	level	_	_
171-9	27895-27898	and	_	_
171-10	27899-27900	3	_	_
171-11	27900-27901	-	_	_
171-12	27901-27906	level	_	_
171-13	27907-27911	HGFs	_	_
171-14	27912-27916	with	_	_
171-15	27917-27920	and	_	_
171-16	27921-27928	without	_	_
171-17	27929-27938	precision	_	_
171-18	27939-27947	feedback	_	_
171-19	27948-27949	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
171-20	27949-27952	see	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
171-21	27953-27963	Supplement	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
171-22	27963-27964	)	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
171-23	27964-27965	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
171-24	27966-27973	leading	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
171-25	27974-27976	to	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
171-26	27977-27981	four	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
171-27	27982-27991	different	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
171-28	27992-28004	hierarchical	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
171-29	28005-28013	learning	_	_
171-30	28014-28020	models	_	_
171-31	28020-28021	:	_	_
171-32	28022-28026	2HGF	_	_
171-33	28026-28027	,	_	_
171-34	28028-28038	2HGFprecfb	_	_
171-35	28038-28039	,	_	_
171-36	28040-28044	3HGF	_	_
171-37	28044-28045	,	_	_
171-38	28046-28049	and	_	_
171-39	28050-28060	3HGFprecfb	_	_
171-40	28060-28061	.	_	_

172-1	28062-28070	Response	_	_
172-2	28071-28077	models	_	_
172-3	28078-28088	Prediction	_	_
172-4	28089-28095	errors	_	_
172-5	28096-28104	relating	_	_
172-6	28105-28107	to	_	_
172-7	28108-28111	the	_	_
172-8	28112-28115	cue	_	_
172-9	28116-28123	feature	_	_
172-10	28124-28128	that	_	_
172-11	28129-28131	is	_	_
172-12	28132-28139	thought	_	_
172-13	28140-28142	to	_	_
172-14	28143-28145	be	_	_
172-15	28146-28150	more	_	_
172-16	28151-28159	relevant	_	_
172-17	28160-28165	might	_	_
172-18	28166-28175	translate	_	_
172-19	28176-28180	more	_	_
172-20	28181-28189	strongly	_	_
172-21	28190-28194	into	_	_
172-22	28195-28203	reaction	_	_
172-23	28204-28209	times	_	_
172-24	28209-28210	,	_	_
172-25	28211-28214	and	_	_
172-26	28215-28218	the	_	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
172-27	28219-28227	aberrant	_	_
172-28	28228-28236	salience	_	_
172-29	28237-28243	effect	_	_
172-30	28244-28249	found	_	_
172-31	28250-28252	in	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument	_
172-32	28253-28256	the	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument	_
172-33	28257-28260	raw	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument	http://maven.renci.org/NeuroBridge/neurobridge#2Level
172-34	28261-28265	data	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument	http://maven.renci.org/NeuroBridge/neurobridge#2Level
172-35	28266-28269	may	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument	http://maven.renci.org/NeuroBridge/neurobridge#2Level
172-36	28270-28272	be	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImagingInstrument	_
172-37	28273-28282	explained	_	_
172-38	28283-28285	as	_	_
172-39	28286-28287	a	_	_
172-40	28288-28292	bias	_	_
172-41	28293-28300	towards	_	_
172-42	28301-28304	one	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol
172-43	28305-28307	of	_	_
172-44	28308-28311	the	_	_
172-45	28312-28322	irrelevant	_	_
172-46	28323-28331	features	_	_
172-47	28332-28334	on	_	_
172-48	28335-28336	a	_	_
172-49	28337-28351	trial-by-trial	_	_
172-50	28352-28357	basis	_	_
172-51	28357-28358	.	_	_

173-1	28359-28363	Both	_	_
173-2	28364-28371	aspects	_	_
173-3	28372-28376	were	_	_
173-4	28377-28387	formalized	_	_
173-5	28388-28390	in	_	_
173-6	28391-28394	the	_	_
173-7	28395-28404	following	_	_
173-8	28405-28409	four	_	_
173-9	28410-28418	response	_	_
173-10	28419-28425	models	_	_
173-11	28425-28426	.	_	_

174-1	28427-28430	The	_	_
174-2	28431-28439	baseline	_	_
174-3	28440-28448	response	_	_
174-4	28449-28454	model	_	_
174-5	28455-28456	(	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging	http://maven.renci.org/NeuroBridge/neurobridge#Asperger'sDisorder
174-6	28456-28459	see	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging	_
174-7	28460-28462	Eq	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging	_
174-8	28463-28464	4	_	_
174-9	28464-28465	)	_	_
174-10	28466-28476	postulates	_	_
174-11	28477-28481	that	_	_
174-12	28482-28496	trial-by-trial	_	_
174-13	28497-28505	reaction	_	_
174-14	28506-28511	times	_	_
174-15	28512-28515	are	_	_
174-16	28516-28517	a	_	_
174-17	28518-28524	linear	_	_
174-18	28525-28533	function	_	_
174-19	28534-28536	of	_	_
174-20	28537-28540	the	_	_
174-21	28541-28545	mean	_	_
174-22	28546-28548	of	_	_
174-23	28549-28552	the	_	_
174-24	28553-28563	prediction	_	_
174-25	28564-28570	errors	_	_
174-26	28571-28573	of	_	_
174-27	28574-28578	both	_	_
174-28	28579-28587	features	_	_
174-29	28588-28589	(	_	_
174-30	28589-28594	4.1.1	_	_
174-31	28594-28595	)	_	_
174-32	28595-28596	,	_	_
174-33	28597-28598	a	_	_
174-34	28599-28607	constant	_	_
174-35	28608-28612	bias	_	_
174-36	28613-28620	towards	_	_
174-37	28621-28624	one	_	_
174-38	28625-28632	feature	_	_
174-39	28633-28646	manifestation	_	_
174-40	28647-28648	(	_	_
174-41	28648-28650	eg	_	_
174-42	28650-28651	,	_	_
174-43	28652-28661	triangles	_	_
174-44	28662-28666	over	_	_
174-45	28667-28674	squares	_	_
174-46	28674-28675	)	_	_
174-47	28676-28679	and	_	_
174-48	28680-28683	the	_	_
174-49	28684-28691	outcome	_	_
174-50	28692-28693	(	_	_
174-51	28693-28695	eg	_	_
174-52	28695-28696	,	_	_
174-53	28697-28703	slower	_	_
174-54	28704-28707	for	_	_
174-55	28708-28715	circles	_	_
174-56	28716-28720	than	_	_
174-57	28721-28724	for	_	_
174-58	28725-28729	coin	_	_
174-59	28730-28736	trials	_	_
174-60	28736-28737	;	_	_
174-61	28738-28743	4.2.1	_	_
174-62	28743-28744	)	_	_
174-63	28744-28745	.	_	_

175-1	28746-28749	The	_	_
175-2	28750-28754	four	_	_
175-3	28755-28758	cue	_	_
175-4	28759-28772	manifestation	_	_
175-5	28773-28780	vectors	_	_
175-6	28781-28782	m	_	_
175-7	28783-28790	reflect	_	_
175-8	28791-28798	whether	_	_
175-9	28799-28802	the	_	_
175-10	28803-28813	respective	_	_
175-11	28814-28828	manifestations	_	_
175-12	28829-28833	were	_	_
175-13	28834-28843	displayed	_	_
175-14	28844-28847	for	_	_
175-15	28848-28853	every	_	_
175-16	28854-28859	trial	_	_
175-17	28860-28861	(	_	_
175-18	28861-28863	eg	_	_
175-19	28863-28864	,	_	_
175-20	28865-28866	1	_	_
175-21	28867-28870	for	_	_
175-22	28871-28880	triangles	_	_
175-23	28881-28884	and	_	_
175-24	28885-28886	0	_	_
175-25	28887-28890	for	_	_
175-26	28891-28898	squares	_	_
175-27	28899-28901	in	_	_
175-28	28902-28911	mtriangle	_	_
175-29	28911-28912	)	_	_
175-30	28912-28913	.	_	_

176-1	28914-28918	This	_	_
176-2	28919-28927	response	_	_
176-3	28928-28933	model	_	_
176-4	28934-28937	was	_	_
176-5	28938-28946	modified	_	_
176-6	28947-28949	in	_	_
176-7	28950-28955	three	_	_
176-8	28956-28960	ways	_	_
176-9	28960-28961	.	_	_

177-1	28962-28964	In	_	_
177-2	28965-28966	a	_	_
177-3	28967-28972	first	_	_
177-4	28973-28985	modification	_	_
177-5	28986-28987	(	_	_
177-6	28987-28992	4.1.2	_	_
177-7	28992-28993	)	_	_
177-8	28993-28994	,	_	_
177-9	28995-28998	the	_	_
177-10	28999-29007	absolute	_	_
177-11	29008-29018	prediction	_	_
177-12	29019-29025	errors	_	_
177-13	29026-29028	of	_	_
177-14	29029-29033	each	_	_
177-15	29034-29041	feature	_	_
177-16	29042-29046	were	_	_
177-17	29047-29055	weighted	_	_
177-18	29056-29065	according	_	_
177-19	29066-29068	to	_	_
177-20	29069-29074	their	_	_
177-21	29075-29085	respective	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
177-22	29086-29095	relevance	_	_
177-23	29096-29102	weight	_	_
177-24	29103-29104	(	_	_
177-25	29104-29107	rel	_	_
177-26	29107-29108	;	_	_
177-27	29109-29110	5	_	_
177-28	29110-29111	)	_	_
177-29	29111-29112	.	_	_

178-1	29113-29116	The	_	_
178-2	29117-29123	latter	_	_
178-3	29124-29126	is	_	_
178-4	29127-29137	formalized	_	_
178-5	29138-29140	as	_	_
178-6	29141-29144	the	_	_
178-7	29145-29153	relative	_	_
178-8	29154-29160	amount	_	_
178-9	29161-29163	of	_	_
178-10	29164-29168	each	_	_
178-11	29169-29176	feature	_	_
178-12	29176-29177	’	_	_
178-13	29177-29178	s	_	_
178-14	29179-29188	precision	_	_
178-15	29189-29194	given	_	_
178-16	29195-29198	the	_	_
178-17	29199-29206	overall	_	_
178-18	29207-29217	precisions	_	_
178-19	29218-29220	of	_	_
178-20	29221-29225	both	_	_
178-21	29226-29234	features	_	_
178-22	29234-29235	.	_	_

179-1	29236-29238	In	_	_
179-2	29239-29240	a	_	_
179-3	29241-29247	second	_	_
179-4	29248-29260	modification	_	_
179-5	29261-29264	and	_	_
179-6	29265-29267	in	_	_
179-7	29268-29272	line	_	_
179-8	29273-29277	with	_	_
179-9	29278-29281	the	_	_
179-10	29282-29290	aberrant	_	_
179-11	29291-29299	salience	_	_
179-12	29300-29306	effect	_	_
179-13	29306-29307	,	_	_
179-14	29308-29311	the	_	_
179-15	29312-29320	constant	_	_
179-16	29321-29325	bias	_	_
179-17	29326-29329	was	_	_
179-18	29330-29338	weighted	_	_
179-19	29339-29348	according	_	_
179-20	29349-29351	to	_	_
179-21	29352-29355	its	_	_
179-22	29356-29363	feature	_	_
179-23	29363-29364	’	_	_
179-24	29364-29365	s	_	_
179-25	29366-29377	irrelevance	_	_
179-26	29378-29379	(	_	_
179-27	29379-29384	irrel	_	_
179-28	29384-29385	;	_	_
179-29	29386-29389	see	_	_
179-30	29390-29392	Eq	_	_
179-31	29393-29398	4.2.2	_	_
179-32	29398-29399	)	_	_
179-33	29399-29400	.	_	_

180-1	29401-29404	The	_	_
180-2	29405-29416	irrelevance	_	_
180-3	29417-29423	weight	_	_
180-4	29424-29426	of	_	_
180-5	29427-29430	one	_	_
180-6	29431-29438	feature	_	_
180-7	29439-29442	was	_	_
180-8	29443-29450	defined	_	_
180-9	29451-29453	as	_	_
180-10	29454-29457	the	_	_
180-11	29458-29467	relevance	_	_
180-12	29468-29474	weight	_	_
180-13	29475-29477	of	_	_
180-14	29478-29481	the	_	_
180-15	29482-29490	opposing	_	_
180-16	29491-29498	feature	_	_
180-17	29499-29500	(	_	_
180-18	29500-29503	see	_	_
180-19	29504-29506	Eq	_	_
180-20	29507-29508	5	_	_
180-21	29508-29509	)	_	_
180-22	29509-29510	.	_	_

181-1	29511-29515	From	_	_
181-2	29516-29519	the	_	_
181-3	29520-29524	four	_	_
181-4	29525-29528	cue	_	_
181-5	29529-29536	feature	_	_
181-6	29537-29547	parameters	_	_
181-7	29548-29549	(	_	_
181-8	29549-29551	β2	_	_
181-9	29551-29552	,	_	_
181-10	29553-29554	…	_	_
181-11	29554-29555	,	_	_
181-12	29556-29558	β5	_	_
181-13	29558-29559	)	_	_
181-14	29560-29563	one	_	_
181-15	29564-29573	composite	_	_
181-16	29574-29583	parameter	_	_
181-17	29584-29587	was	_	_
181-18	29588-29598	calculated	_	_
181-19	29599-29601	in	_	_
181-20	29602-29605	two	_	_
181-21	29606-29611	steps	_	_
181-22	29611-29612	.	_	_

182-1	29613-29618	First	_	_
182-2	29618-29619	,	_	_
182-3	29620-29623	the	_	_
182-4	29624-29634	individual	_	_
182-5	29635-29643	absolute	_	_
182-6	29644-29655	differences	_	_
182-7	29656-29663	between	_	_
182-8	29664-29667	the	_	_
182-9	29668-29670	β2	_	_
182-10	29671-29674	and	_	_
182-11	29675-29677	β3	_	_
182-12	29678-29681	for	_	_
182-13	29682-29693	irrelevance	_	_
182-14	29694-29702	weighted	_	_
182-15	29703-29717	manifestations	_	_
182-16	29718-29724	within	_	_
182-17	29725-29730	color	_	_
182-18	29731-29732	(	_	_
182-19	29732-29735	and	_	_
182-20	29736-29743	between	_	_
182-21	29744-29747	the	_	_
182-22	29748-29750	β4	_	_
182-23	29751-29754	and	_	_
182-24	29755-29757	β5	_	_
182-25	29758-29761	for	_	_
182-26	29762-29767	shape	_	_
182-27	29768-29782	manifestations	_	_
182-28	29782-29783	)	_	_
182-29	29784-29788	were	_	_
182-30	29789-29799	calculated	_	_
182-31	29799-29800	.	_	_

183-1	29801-29805	Then	_	_
183-2	29805-29806	,	_	_
183-3	29807-29811	they	_	_
183-4	29812-29816	were	_	_
183-5	29817-29826	collapsed	_	_
183-6	29827-29833	across	_	_
183-7	29834-29839	color	_	_
183-8	29840-29843	and	_	_
183-9	29844-29849	shape	_	_
183-10	29850-29852	to	_	_
183-11	29853-29860	achieve	_	_
183-12	29861-29864	one	_	_
183-13	29865-29874	parameter	_	_
183-14	29875-29887	βirrelevance	_	_
183-15	29888-29897	capturing	_	_
183-16	29898-29901	the	_	_
183-17	29902-29906	bias	_	_
183-18	29907-29914	towards	_	_
183-19	29915-29918	one	_	_
183-20	29919-29922	cue	_	_
183-21	29923-29930	feature	_	_
183-22	29931-29944	manifestation	_	_
183-23	29945-29949	that	_	_
183-24	29950-29959	increased	_	_
183-25	29960-29964	with	_	_
183-26	29965-29975	subjective	_	_
183-27	29976-29987	irrelevance	_	_
183-28	29987-29988	.	_	_

184-1	29989-29993	Thus	_	_
184-2	29993-29994	,	_	_
184-3	29995-29997	we	_	_
184-4	29998-30006	compared	_	_
184-5	30007-30011	four	_	_
184-6	30012-30021	different	_	_
184-7	30022-30030	response	_	_
184-8	30031-30037	models	_	_
184-9	30037-30038	:	_	_
184-10	30039-30042	the	_	_
184-11	30043-30051	baseline	_	_
184-12	30052-30057	model	_	_
184-13	30058-30059	(	_	_
184-14	30059-30061	Eq	_	_
184-15	30062-30063	4	_	_
184-16	30063-30064	)	_	_
184-17	30064-30065	,	_	_
184-18	30066-30069	the	_	_
184-19	30070-30078	baseline	_	_
184-20	30079-30084	model	_	_
184-21	30085-30089	with	_	_
184-22	30090-30099	relevance	_	_
184-23	30100-30108	weighted	_	_
184-24	30109-30117	absolute	_	_
184-25	30118-30128	prediction	_	_
184-26	30129-30135	errors	_	_
184-27	30136-30137	(	_	_
184-28	30137-30139	Eq	_	_
184-29	30140-30141	4	_	_
184-30	30142-30146	with	_	_
184-31	30147-30159	modification	_	_
184-32	30160-30164	term	_	_
184-33	30165-30170	4.1.2	_	_
184-34	30170-30171	;	_	_
184-35	30172-30177	RelPE	_	_
184-36	30177-30178	)	_	_
184-37	30178-30179	,	_	_
184-38	30180-30183	the	_	_
184-39	30184-30192	baseline	_	_
184-40	30193-30198	model	_	_
184-41	30199-30203	with	_	_
184-42	30204-30208	only	_	_
184-43	30209-30212	the	_	_
184-44	30213-30224	irrelevance	_	_
184-45	30225-30229	bias	_	_
184-46	30230-30231	(	_	_
184-47	30231-30233	Eq	_	_
184-48	30234-30235	4	_	_
184-49	30236-30240	with	_	_
184-50	30241-30253	modification	_	_
184-51	30254-30258	term	_	_
184-52	30259-30264	4.2.2	_	_
184-53	30264-30265	;	_	_
184-54	30266-30275	IrrelBias	_	_
184-55	30275-30276	)	_	_
184-56	30276-30277	,	_	_
184-57	30278-30281	and	_	_
184-58	30282-30283	a	_	_
184-59	30284-30288	full	_	_
184-60	30289-30294	model	_	_
184-61	30295-30299	with	_	_
184-62	30300-30304	both	_	_
184-63	30305-30318	modifications	_	_
184-64	30319-30320	(	_	_
184-65	30320-30322	Eq	_	_
184-66	30323-30324	4	_	_
184-67	30325-30329	with	_	_
184-68	30330-30342	modification	_	_
184-69	30343-30348	terms	_	_
184-70	30349-30354	4.1.2	_	_
184-71	30355-30358	and	_	_
184-72	30359-30364	4.2.2	_	_
184-73	30364-30365	;	_	_
184-74	30366-30371	RelPE	_	_
184-75	30371-30372	+	_	_
184-76	30372-30381	IrrelBias	_	_
184-77	30381-30382	)	_	_
184-78	30382-30383	.	_	_

185-1	30384-30388	This	_	_
185-2	30389-30392	led	_	_
185-3	30393-30395	to	_	_
185-4	30396-30397	a	_	_
185-5	30398-30403	total	_	_
185-6	30404-30409	model	_	_
185-7	30410-30415	space	_	_
185-8	30416-30418	of	_	_
185-9	30419-30421	16	_	_
185-10	30422-30427	model	_	_
185-11	30428-30440	combinations	_	_
185-12	30441-30442	(	_	_
185-13	30442-30445	see	_	_
185-14	30446-30452	Figure	_	_
185-15	30453-30455	S1	_	_
185-16	30455-30456	)	_	_
185-17	30456-30457	.	_	_

186-1	30458-30463	Model	_	_
186-2	30464-30471	fitting	_	_
186-3	30472-30475	and	_	_
186-4	30476-30484	Bayesian	_	_
186-5	30485-30490	model	_	_
186-6	30491-30501	comparison	_	_
186-7	30502-30505	All	_	_
186-8	30506-30512	models	_	_
186-9	30513-30517	were	_	_
186-10	30518-30524	fitted	_	_
186-11	30525-30530	using	_	_
186-12	30531-30534	the	_	_
186-13	30535-30538	HGF	_	_
186-14	30539-30546	toolbox	_	_
186-15	30547-30551	4.15	_	_
186-16	30552-30554	as	_	_
186-17	30555-30559	part	_	_
186-18	30560-30562	of	_	_
186-19	30563-30566	TNU	_	_
186-20	30567-30577	Algorithms	_	_
186-21	30578-30581	for	_	_
186-22	30582-30602	Psychiatry-Advancing	_	_
186-23	30603-30610	Science	_	_
186-24	30611-30612	(	_	_
186-25	30612-30617	TAPAS	_	_
186-26	30617-30618	,	_	_
186-27	30619-30623	http	_	_
186-28	30623-30624	:	_	_
186-29	30624-30625	/	_	_
186-30	30625-30626	/	_	_
186-31	30626-30660	www.translationalneuromodeling.org	_	_
186-32	30660-30661	/	_	_
186-33	30661-30666	tapas	_	_
186-34	30666-30667	/	_	_
186-35	30667-30668	)	_	_
186-36	30668-30669	.	_	_

187-1	30670-30673	For	_	_
187-2	30674-30686	optimization	_	_
187-3	30686-30687	,	_	_
187-4	30688-30689	a	_	_
187-5	30690-30702	quasi-Newton	_	_
187-6	30703-30715	optimization	_	_
187-7	30716-30725	algorithm	_	_
187-8	30726-30729	was	_	_
187-9	30730-30737	applied	_	_
187-10	30737-30738	.	_	_

188-1	30739-30741	We	_	_
188-2	30742-30746	used	_	_
188-3	30747-30761	random-effects	_	_
188-4	30762-30770	Bayesian	_	_
188-5	30771-30776	Model	_	_
188-6	30777-30786	Selection	_	_
188-7	30787-30788	[	_	_
188-8	30788-30791	BMS	_	_
188-9	30791-30792	,	_	_
188-10	30793-30800	spm_BMS	_	_
188-11	30801-30803	in	_	_
188-12	30804-30809	SPM12	_	_
188-13	30809-30810	,	_	_
188-14	30811-30829	www.fil.ion.ucl.uk	_	_
188-15	30829-30830	/	_	_
188-16	30830-30833	spm	_	_
188-17	30833-30834	;	_	_
188-18	30835-30836	]	_	_
188-19	30837-30840	for	_	_
188-20	30841-30845	each	_	_
188-21	30846-30853	subject	_	_
188-22	30853-30854	’	_	_
188-23	30854-30855	s	_	_
188-24	30856-30859	and	_	_
188-25	30860-30864	each	_	_
188-26	30865-30870	model	_	_
188-27	30870-30871	’	_	_
188-28	30871-30872	s	_	_
188-29	30873-30881	negative	_	_
188-30	30882-30886	free	_	_
188-31	30887-30893	energy	_	_
188-32	30894-30895	(	_	_
188-33	30895-30897	as	_	_
188-34	30898-30900	an	_	_
188-35	30901-30914	approximation	_	_
188-36	30915-30917	to	_	_
188-37	30918-30927	log-model	_	_
188-38	30928-30936	evidence	_	_
188-39	30936-30937	)	_	_
188-40	30938-30940	in	_	_
188-41	30941-30946	order	_	_
188-42	30947-30949	to	_	_
188-43	30950-30958	identify	_	_
188-44	30959-30964	which	_	_
188-45	30965-30967	of	_	_
188-46	30968-30971	the	_	_
188-47	30972-30981	competing	_	_
188-48	30982-30988	models	_	_
188-49	30989-30993	best	_	_
188-50	30994-31003	explained	_	_
188-51	31004-31007	the	_	_
188-52	31008-31016	subjects	_	_
188-53	31016-31017	’	_	_
188-54	31018-31026	response	_	_
188-55	31027-31031	time	_	_
188-56	31032-31036	data	_	_
188-57	31036-31037	.	_	_

189-1	31038-31041	BMS	_	_
189-2	31042-31047	takes	_	_
189-3	31048-31052	into	_	_
189-4	31053-31060	account	_	_
189-5	31061-31069	accuracy	_	_
189-6	31070-31072	of	_	_
189-7	31073-31077	each	_	_
189-8	31078-31083	model	_	_
189-9	31084-31087	and	_	_
189-10	31088-31092	also	_	_
189-11	31093-31102	penalizes	_	_
189-12	31103-31106	for	_	_
189-13	31107-31117	complexity	_	_
189-14	31117-31118	.	_	_

190-1	31119-31121	It	_	_
190-2	31122-31130	accounts	_	_
190-3	31131-31134	for	_	_
190-4	31135-31148	heterogeneity	_	_
190-5	31149-31155	across	_	_
190-6	31156-31164	subjects	_	_
190-7	31165-31168	and	_	_
190-8	31169-31175	treats	_	_
190-9	31176-31180	each	_	_
190-10	31181-31186	model	_	_
190-11	31187-31189	as	_	_
190-12	31190-31191	a	_	_
190-13	31192-31198	random	_	_
190-14	31199-31207	variable	_	_
190-15	31208-31210	in	_	_
190-16	31211-31214	the	_	_
190-17	31215-31225	population	_	_
190-18	31225-31226	.	_	_

191-1	31227-31229	We	_	_
191-2	31230-31236	report	_	_
191-3	31237-31246	protected	_	_
191-4	31247-31257	exceedance	_	_
191-5	31258-31271	probabilities	_	_
191-6	31272-31275	for	_	_
191-7	31276-31280	each	_	_
191-8	31281-31286	model	_	_
191-9	31287-31288	(	_	_
191-10	31288-31291	PXP	_	_
191-11	31291-31292	)	_	_
191-12	31293-31296	and	_	_
191-13	31297-31306	posterior	_	_
191-14	31307-31320	probabilities	_	_
191-15	31321-31322	(	_	_
191-16	31322-31324	PP	_	_
191-17	31324-31325	)	_	_
191-18	31326-31328	as	_	_
191-19	31329-31333	well	_	_
191-20	31334-31336	as	_	_
191-21	31337-31347	exceedance	_	_
191-22	31348-31361	probabilities	_	_
191-23	31362-31363	(	_	_
191-24	31363-31365	XP	_	_
191-25	31365-31366	)	_	_
191-26	31367-31370	for	_	_
191-27	31371-31376	model	_	_
191-28	31377-31385	families	_	_
191-29	31386-31387	(	_	_
191-30	31387-31390	HGF	_	_
191-31	31391-31393	vs	_	_
191-32	31393-31394	.	_	_

192-1	31395-31404	HGFprecfb	_	_
192-2	31404-31405	;	_	_
192-3	31406-31410	2HGF	_	_
192-4	31411-31413	vs	_	_
192-5	31413-31414	.	_	_
192-6	31415-31419	3HGF	_	_
192-7	31419-31420	;	_	_
192-8	31421-31423	BL	_	_
192-9	31424-31426	vs	_	_
192-10	31426-31427	.	_	_

193-1	31428-31433	RelPE	_	_
193-2	31434-31436	vs	_	_
193-3	31436-31437	.	_	_

194-1	31438-31447	IrrelBias	_	_
194-2	31448-31450	vs	_	_
194-3	31450-31451	.	_	_

195-1	31452-31457	RelPE	_	_
195-2	31457-31458	+	_	_
195-3	31458-31467	IrrelBias	_	_
195-4	31467-31468	)	_	_
195-5	31468-31469	.	_	_

196-1	31470-31473	The	_	_
196-2	31474-31476	XP	_	_
196-3	31477-31486	describes	_	_
196-4	31487-31490	the	_	_
196-5	31491-31499	relative	_	_
196-6	31500-31511	probability	_	_
196-7	31512-31516	that	_	_
196-8	31517-31520	the	_	_
196-9	31521-31526	model	_	_
196-10	31527-31532	would	_	_
196-11	31533-31539	better	_	_
196-12	31540-31549	replicate	_	_
196-13	31550-31553	the	_	_
196-14	31554-31558	data	_	_
196-15	31559-31561	in	_	_
196-16	31562-31572	comparison	_	_
196-17	31573-31577	with	_	_
196-18	31578-31581	the	_	_
196-19	31582-31587	other	_	_
196-20	31588-31594	models	_	_
196-21	31594-31595	.	_	_

197-1	31596-31599	The	_	_
197-2	31600-31603	PXP	_	_
197-3	31604-31608	that	_	_
197-4	31609-31617	governed	_	_
197-5	31618-31621	our	_	_
197-6	31622-31627	model	_	_
197-7	31628-31637	selection	_	_
197-8	31638-31646	protects	_	_
197-9	31647-31654	against	_	_
197-10	31655-31658	the	_	_
197-11	31659-31660	‘	_	_
197-12	31660-31664	null	_	_
197-13	31664-31665	’	_	_
197-14	31666-31677	possibility	_	_
197-15	31678-31682	that	_	_
197-16	31683-31688	there	_	_
197-17	31689-31692	are	_	_
197-18	31693-31695	no	_	_
197-19	31696-31707	differences	_	_
197-20	31708-31710	in	_	_
197-21	31711-31714	the	_	_
197-22	31715-31725	likelihood	_	_
197-23	31726-31728	of	_	_
197-24	31729-31735	models	_	_
197-25	31736-31742	across	_	_
197-26	31743-31746	the	_	_
197-27	31747-31757	population	_	_
197-28	31757-31758	.	_	_

198-1	31759-31769	Simulation	_	_
198-2	31770-31778	analyses	_	_
198-3	31779-31784	Based	_	_
198-4	31785-31787	on	_	_
198-5	31788-31791	the	_	_
198-6	31792-31801	estimated	_	_
198-7	31802-31812	individual	_	_
198-8	31813-31823	parameters	_	_
198-9	31824-31828	from	_	_
198-10	31829-31832	the	_	_
198-11	31833-31845	best-fitting	_	_
198-12	31846-31851	model	_	_
198-13	31851-31852	,	_	_
198-14	31853-31855	we	_	_
198-15	31856-31865	simulated	_	_
198-16	31866-31880	trial-by-trial	_	_
198-17	31881-31889	reaction	_	_
198-18	31890-31894	time	_	_
198-19	31895-31899	data	_	_
198-20	31899-31900	.	_	_

199-1	31901-31903	In	_	_
199-2	31904-31912	addition	_	_
199-3	31913-31915	to	_	_
199-4	31916-31919	the	_	_
199-5	31920-31928	Bayesian	_	_
199-6	31929-31934	model	_	_
199-7	31935-31945	comparison	_	_
199-8	31945-31946	,	_	_
199-9	31947-31949	we	_	_
199-10	31950-31956	tested	_	_
199-11	31957-31960	the	_	_
199-12	31961-31966	model	_	_
199-13	31966-31967	’	_	_
199-14	31967-31968	s	_	_
199-15	31969-31980	credibility	_	_
199-16	31981-31983	by	_	_
199-17	31984-31992	carrying	_	_
199-18	31993-31996	out	_	_
199-19	31997-32000	the	_	_
199-20	32001-32005	same	_	_
199-21	32006-32014	analyses	_	_
199-22	32015-32017	as	_	_
199-23	32018-32020	in	_	_
199-24	32021-32024	the	_	_
199-25	32025-32028	raw	_	_
199-26	32029-32033	data	_	_
199-27	32034-32041	section	_	_
199-28	32042-32044	on	_	_
199-29	32045-32048	the	_	_
199-30	32049-32058	simulated	_	_
199-31	32059-32063	data	_	_
199-32	32064-32065	(	_	_
199-33	32065-32066	(	_	_
199-34	32066-32067	1	_	_
199-35	32067-32068	)	_	_
199-36	32069-32081	Expectedness	_	_
199-37	32081-32082	*	_	_
199-38	32082-32087	Group	_	_
199-39	32088-32093	ANOVA	_	_
199-40	32093-32094	,	_	_
199-41	32095-32096	(	_	_
199-42	32096-32097	2	_	_
199-43	32097-32098	)	_	_
199-44	32099-32108	Condition	_	_
199-45	32108-32109	*	_	_
199-46	32109-32113	Time	_	_
199-47	32113-32114	*	_	_
199-48	32114-32119	Group	_	_
199-49	32120-32125	ANOVA	_	_
199-50	32125-32126	,	_	_
199-51	32127-32128	(	_	_
199-52	32128-32129	3	_	_
199-53	32129-32130	)	_	_
199-54	32131-32132	‘	_	_
199-55	32132-32138	ground	_	_
199-56	32139-32144	truth	_	_
199-57	32144-32145	’	_	_
199-58	32146-32154	aberrant	_	_
199-59	32155-32163	salience	_	_
199-60	32164-32169	group	_	_
199-61	32170-32181	differences	_	_
199-62	32181-32182	)	_	_
199-63	32182-32183	.	_	_

200-1	32184-32189	Using	_	_
200-2	32190-32194	this	_	_
200-3	32195-32203	approach	_	_
200-4	32203-32204	,	_	_
200-5	32205-32207	we	_	_
200-6	32208-32215	checked	_	_
200-7	32216-32223	whether	_	_
200-8	32224-32227	the	_	_
200-9	32228-32233	model	_	_
200-10	32234-32237	was	_	_
200-11	32238-32245	capable	_	_
200-12	32246-32248	of	_	_
200-13	32249-32260	reproducing	_	_
200-14	32261-32264	the	_	_
200-15	32265-32275	meaningful	_	_
200-16	32276-32283	effects	_	_
200-17	32284-32287	and	_	_
200-18	32288-32293	group	_	_
200-19	32294-32305	differences	_	_
200-20	32306-32310	that	_	_
200-21	32311-32315	were	_	_
200-22	32316-32323	evident	_	_
200-23	32324-32326	in	_	_
200-24	32327-32330	the	_	_
200-25	32331-32335	data	_	_
200-26	32335-32336	.	_	_

201-1	32337-32347	Functional	_	_
201-2	32348-32356	magnetic	_	_
201-3	32357-32366	resonance	_	_
201-4	32367-32374	imaging	_	_
201-5	32375-32378	For	_	_
201-6	32379-32385	single	_	_
201-7	32386-32389	and	_	_
201-8	32390-32395	group	_	_
201-9	32396-32406	statistics	_	_
201-10	32406-32407	,	_	_
201-11	32408-32410	an	_	_
201-12	32411-32424	event-related	_	_
201-13	32425-32433	analysis	_	_
201-14	32434-32437	was	_	_
201-15	32438-32445	applied	_	_
201-16	32446-32451	using	_	_
201-17	32452-32455	the	_	_
201-18	32456-32463	general	_	_
201-19	32464-32470	linear	_	_
201-20	32471-32476	model	_	_
201-21	32477-32478	(	_	_
201-22	32478-32481	GLM	_	_
201-23	32481-32482	)	_	_
201-24	32483-32491	approach	_	_
201-25	32492-32494	as	_	_
201-26	32495-32506	implemented	_	_
201-27	32507-32509	in	_	_
201-28	32510-32515	SPM12	_	_
201-29	32516-32517	(	_	_
201-30	32517-32521	http	_	_
201-31	32521-32522	:	_	_
201-32	32522-32523	/	_	_
201-33	32523-32524	/	_	_
201-34	32524-32545	www.fil.ion.ucl.ac.uk	_	_
201-35	32545-32546	/	_	_
201-36	32546-32549	spm	_	_
201-37	32549-32550	/	_	_
201-38	32550-32558	software	_	_
201-39	32558-32559	/	_	_
201-40	32559-32564	spm12	_	_
201-41	32564-32565	/	_	_
201-42	32565-32566	)	_	_
201-43	32566-32567	.	_	_

202-1	32568-32570	On	_	_
202-2	32571-32574	the	_	_
202-3	32575-32581	single	_	_
202-4	32582-32589	subject	_	_
202-5	32590-32595	level	_	_
202-6	32595-32596	,	_	_
202-7	32597-32600	the	_	_
202-8	32601-32608	outcome	_	_
202-9	32609-32615	onsets	_	_
202-10	32616-32620	were	_	_
202-11	32621-32630	convolved	_	_
202-12	32631-32635	with	_	_
202-13	32636-32639	the	_	_
202-14	32640-32651	hemodynamic	_	_
202-15	32652-32660	response	_	_
202-16	32661-32669	function	_	_
202-17	32670-32673	and	_	_
202-18	32674-32677	its	_	_
202-19	32678-32686	temporal	_	_
202-20	32687-32697	derivative	_	_
202-21	32697-32698	.	_	_

203-1	32699-32701	As	_	_
203-2	32702-32712	parametric	_	_
203-3	32713-32722	modulator	_	_
203-4	32722-32723	,	_	_
203-5	32724-32727	the	_	_
203-6	32728-32732	mean	_	_
203-7	32733-32735	of	_	_
203-8	32736-32739	the	_	_
203-9	32740-32749	relevance	_	_
203-10	32750-32758	weighted	_	_
203-11	32759-32767	absolute	_	_
203-12	32768-32778	prediction	_	_
203-13	32779-32785	errors	_	_
203-14	32786-32788	of	_	_
203-15	32789-32792	the	_	_
203-16	32793-32797	best	_	_
203-17	32798-32805	fitting	_	_
203-18	32806-32811	model	_	_
203-19	32812-32813	(	_	_
203-20	32813-32823	2HGF-RelPe	_	_
203-21	32823-32824	+	_	_
203-22	32824-32833	IrrelBias	_	_
203-23	32833-32834	)	_	_
203-24	32835-32838	was	_	_
203-25	32839-32849	introduced	_	_
203-26	32849-32850	,	_	_
203-27	32851-32863	representing	_	_
203-28	32864-32867	how	_	_
203-29	32868-32878	unexpected	_	_
203-30	32879-32882	and	_	_
203-31	32883-32890	salient	_	_
203-32	32891-32894	the	_	_
203-33	32895-32903	observed	_	_
203-34	32904-32911	outcome	_	_
203-35	32912-32915	was	_	_
203-36	32916-32921	based	_	_
203-37	32922-32924	on	_	_
203-38	32925-32928	the	_	_
203-39	32929-32937	subjects	_	_
203-40	32937-32938	’	_	_
203-41	32939-32946	learned	_	_
203-42	32947-32959	expectations	_	_
203-43	32960-32965	about	_	_
203-44	32966-32969	the	_	_
203-45	32970-32973	two	_	_
203-46	32974-32977	cue	_	_
203-47	32978-32986	features	_	_
203-48	32986-32987	.	_	_

204-1	32988-32998	Regressors	_	_
204-2	32999-33001	of	_	_
204-3	33002-33004	no	_	_
204-4	33005-33013	interest	_	_
204-5	33014-33018	were	_	_
204-6	33019-33021	no	_	_
204-7	33022-33030	response	_	_
204-8	33031-33037	trials	_	_
204-9	33037-33038	,	_	_
204-10	33039-33045	trials	_	_
204-11	33046-33050	with	_	_
204-12	33051-33059	reaction	_	_
204-13	33060-33065	times	_	_
204-14	33065-33066	>	_	_
204-15	33066-33069	1.5	_	_
204-16	33070-33077	seconds	_	_
204-17	33078-33081	and	_	_
204-18	33082-33083	<	_	_
204-19	33083-33086	150	_	_
204-20	33087-33099	milliseconds	_	_
204-21	33099-33100	,	_	_
204-22	33101-33112	realignment	_	_
204-23	33113-33123	parameters	_	_
204-24	33124-33128	with	_	_
204-25	33129-33134	their	_	_
204-26	33135-33140	first	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
204-27	33141-33149	temporal	_	_
204-28	33150-33160	derivative	_	_
204-29	33161-33163	of	_	_
204-30	33164-33177	translational	_	_
204-31	33178-33186	movement	_	_
204-32	33186-33187	,	_	_
204-33	33188-33191	and	_	_
204-34	33192-33195	one	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
204-35	33196-33205	regressor	_	_
204-36	33206-33209	for	_	_
204-37	33210-33215	scans	_	_
204-38	33216-33220	with	_	_
204-39	33221-33222	>	_	_
204-40	33222-33225	1mm	_	_
204-41	33226-33238	scan-to-scan	_	_
204-42	33239-33247	movement	_	_
204-43	33247-33248	.	_	_

205-1	33249-33252	For	_	_
205-2	33253-33259	random	_	_
205-3	33260-33267	effects	_	_
205-4	33268-33279	group-level	_	_
205-5	33280-33288	analysis	_	_
205-6	33288-33289	,	_	_
205-7	33290-33293	the	_	_
205-8	33294-33304	individual	_	_
205-9	33305-33313	contrast	_	_
205-10	33314-33320	images	_	_
205-11	33321-33324	for	_	_
205-12	33325-33329	mean	_	_
205-13	33330-33339	relevance	_	_
205-14	33340-33348	weighted	_	_
205-15	33349-33352	PEs	_	_
205-16	33353-33357	were	_	_
205-17	33358-33362	used	_	_
205-18	33363-33365	in	_	_
205-19	33366-33367	a	_	_
205-20	33368-33378	two-sample	_	_
205-21	33379-33385	t-test	_	_
205-22	33386-33389	for	_	_
205-23	33390-33403	between-group	_	_
205-24	33404-33415	comparisons	_	_
205-25	33416-33417	(	_	_
205-26	33417-33425	controls	_	_
205-27	33426-33428	vs	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
205-28	33428-33429	.	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	_
205-29	33430-33438	patients	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	_
205-30	33438-33439	)	_	_
205-31	33439-33440	.	_	_

206-1	33441-33452	Explorative	_	_
206-2	33453-33461	analysis	_	_
206-3	33462-33468	probed	_	_
206-4	33469-33472	the	_	_
206-5	33473-33484	association	_	_
206-6	33485-33492	between	_	_
206-7	33493-33498	model	_	_
206-8	33499-33508	parameter	_	_
206-9	33509-33521	βirrelevance	_	_
206-10	33522-33525	and	_	_
206-11	33526-33532	neural	_	_
206-12	33533-33542	relevance	_	_
206-13	33543-33551	weighted	_	_
206-14	33552-33554	PE	_	_
206-15	33555-33562	signals	_	_
206-16	33563-33565	in	_	_
206-17	33566-33579	schizophrenia	_	_
206-18	33580-33588	patients	_	_
206-19	33588-33589	.	_	_

207-1	33590-33595	Hence	_	_
207-2	33595-33596	,	_	_
207-3	33597-33612	interindividual	_	_
207-4	33613-33625	βirrelevance	_	_
207-5	33626-33632	scores	_	_
207-6	33633-33637	were	_	_
207-7	33638-33648	introduced	_	_
207-8	33649-33651	as	_	_
207-9	33652-33653	a	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
207-10	33654-33663	covariate	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
207-11	33664-33666	in	_	_
207-12	33667-33668	a	_	_
207-13	33669-33679	one-sample	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
207-14	33680-33686	t-test	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
207-15	33687-33692	using	_	_
207-16	33693-33696	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
207-17	33697-33701	Mean	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
207-18	33702-33711	relevance	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
207-19	33712-33720	weighted	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
207-20	33721-33723	PE	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
207-21	33724-33732	contrast	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
207-22	33732-33733	.	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_

208-1	33734-33741	Results	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
208-2	33742-33745	are	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
208-3	33746-33754	reported	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
208-4	33755-33760	using	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
208-5	33761-33764	FWE	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
208-6	33765-33775	correction	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
208-7	33776-33778	at	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
208-8	33779-33782	the	_	_
208-9	33783-33788	voxel	_	_
208-10	33789-33794	level	_	_
208-11	33795-33801	across	_	_
208-12	33802-33805	the	_	_
208-13	33806-33811	whole	_	_
208-14	33812-33817	brain	_	_
208-15	33817-33818	.	_	_

209-1	33819-33824	Based	_	_
209-2	33825-33827	on	_	_
209-3	33828-33831	our	_	_
209-4	33832-33842	hypothesis	_	_
209-5	33843-33853	concerning	_	_
209-6	33854-33865	activations	_	_
209-7	33866-33868	in	_	_
209-8	33869-33874	areas	_	_
209-9	33875-33885	previously	_	_
209-10	33886-33891	shown	_	_
209-11	33892-33894	to	_	_
209-12	33895-33899	code	_	_
209-13	33900-33908	salience	_	_
209-14	33909-33913	such	_	_
209-15	33914-33916	as	_	_
209-16	33917-33920	the	_	_
209-17	33921-33924	ACC	_	_
209-18	33925-33928	and	_	_
209-19	33929-33935	insula	_	_
209-20	33935-33936	,	_	_
209-21	33937-33943	namely	_	_
209-22	33944-33947	the	_	_
209-23	33948-33957	so-called	_	_
209-24	33958-33966	salience	_	_
209-25	33967-33974	network	_	_
209-26	33974-33975	,	_	_
209-27	33976-33979	and	_	_
209-28	33980-33983	the	_	_
209-29	33984-33991	nucleus	_	_
209-30	33992-34001	accumbens	_	_
209-31	34001-34002	,	_	_
209-32	34003-34005	we	_	_
209-33	34006-34013	applied	_	_
209-34	34014-34019	small	_	_
209-35	34020-34026	volume	_	_
209-36	34027-34037	correction	_	_
209-37	34038-34040	at	_	_
209-38	34041-34044	the	_	_
209-39	34045-34050	voxel	_	_
209-40	34051-34056	level	_	_
209-41	34057-34060	for	_	_
209-42	34061-34064	the	_	_
209-43	34065-34075	respective	_	_
209-44	34076-34085	bilateral	_	_
209-45	34086-34096	anatomical	_	_
209-46	34097-34102	masks	_	_
209-47	34103-34110	derived	_	_
209-48	34111-34115	from	_	_
209-49	34116-34119	the	_	_
209-50	34120-34123	WFU	_	_
209-51	34124-34133	PickAtlas	_	_
209-52	34134-34135	(	_	_
209-53	34135-34139	http	_	_
209-54	34139-34140	:	_	_
209-55	34140-34141	/	_	_
209-56	34141-34142	/	_	_
209-57	34142-34157	fmri.wfubmc.edu	_	_
209-58	34157-34158	/	_	_
209-59	34158-34166	software	_	_
209-60	34166-34167	/	_	_
209-61	34167-34176	pickatlas	_	_
209-62	34176-34177	)	_	_
209-63	34177-34178	.	_	_

210-1	34179-34183	Thus	_	_
210-2	34183-34184	,	_	_
210-3	34185-34190	three	_	_
210-4	34191-34195	VOIs	_	_
210-5	34196-34200	were	_	_
210-6	34201-34205	used	_	_
210-7	34206-34209	for	_	_
210-8	34210-34215	small	_	_
210-9	34216-34222	volume	_	_
210-10	34223-34233	correction	_	_
210-11	34234-34236	at	_	_
210-12	34237-34241	pFWE	_	_
210-13	34241-34242	<	_	_
210-14	34242-34246	0.05	_	_
210-15	34247-34250	and	_	_
210-16	34251-34253	we	_	_
210-17	34254-34262	indicate	_	_
210-18	34263-34268	which	_	_
210-19	34269-34276	results	_	_
210-20	34277-34284	survive	_	_
210-21	34285-34295	Bonferroni	_	_
210-22	34296-34306	correction	_	_
210-23	34307-34310	for	_	_
210-24	34311-34316	three	_	_
210-25	34317-34322	tests	_	_
210-26	34322-34323	.	_	_


















































































































